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Abstract: Protein kinase D (PKD) is a family of serine/threonine protein kinases operating in the
signaling network of the second messenger diacylglycerol. The three family members, PKD1, PKD2,
and PKD3, are activated by a variety of extracellular stimuli and transduce cell signals affecting many
aspects of basic cell functions including secretion, migration, proliferation, survival, angiogenesis,
and immune response. Dysregulation of PKD in expression and activity has been detected in many
human diseases. Further loss- or gain-of-function studies at cellular levels and in animal models
provide strong support for crucial roles of PKD in many pathological conditions, including cancer,
metabolic disorders, cardiac diseases, central nervous system disorders, inflammatory diseases,
and immune dysregulation. Complexity in enzymatic regulation and function is evident as PKD
isoforms may act differently in different biological systems and disease models, and understanding
the molecular mechanisms underlying these differences and their biological significance in vivo is
essential for the development of safer and more effective PKD-targeted therapies. In this review,
to provide a global understanding of PKD function, we present an overview of the PKD family in
several major human diseases with more focus on cancer-associated biological processes.
Keywords: protein kinase D; diseases; cancer; cardiovascular diseases; CNS disorders; metabolic
diseases; inflammation; immune dysregulation
1. Introduction
Protein kinase D (PKD) was discovered near the turn of the second millennium, with
PKD1 first reported in 1994 [1,2], followed by PKD3 in 1999 [3] and PKD2 in 2001 [4]. Due
to the presence of a diacylglycerol (DAG)-binding C1 domain in its structure, PKD was
initially classified as an atypical protein kinase C (PKC) and given the name PKCµ for
human PKD1 and PKCν for PKD3. Later, recognizing the similarity of its catalytic domain
to Ca2+/calmodulin-dependent protein kinases (CAMKs), PKD was reclassified into the
CAMK group in the human kinome. Interestingly, PKD not only binds DAG but also
is activated by PKC through direct phosphorylation, a unique feature allowing PKD to
integrate signal inputs from both DAG and PKC.
In the past two decades, extensive progress has been made towards the understanding
of PKD structure, regulation, function, and signaling mechanisms. PKD has now emerged
as a key signaling node in the DAG network, activated by a variety of cellular stimuli
including growth factors, G protein-coupled receptor (GPCR) agonists, hormones, bioac-
tive peptides, cellular stresses, and cytokines/chemokines, and coordinately regulates
various downstream cellular processes, such as proliferation, survival, motility, secretion,
and gene expression. PKD resides or can be mobilized to different subcellular locations,
including the plasma membrane, Golgi, mitochondria, and nucleus, to carry out unique
functions. Coinciding with its important roles in normal biology, dysregulation of PKD has
detrimental impacts and associates with a variety of pathological conditions and diseases
such as cancer, cardiac diseases, metabolic disorders, inflammatory diseases, neuronal
dysfunctions, and immune dysregulation.
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In this review, we outline past findings and new studies on PKD in various pathologi-
cal conditions and diseases. Due to the space limitation, we only highlight the key findings
that link PKD to specific diseases and their implications in therapy. In areas that have been
more extensively studied, such as cancer, the discussion focuses on the diverse and often
interconnected roles of PKD underlying the pathogenic processes of the disease.
2. PKD Structure and Regulation
2.1. Structure, Isoforms, and Expression/Tissue Distribution
The family of PKD is evolutionarily highly conserved with three isoforms (PKD1,
PKD2, and PKD3) identified in mammals. The three PKDs are similar in sizes (912, 878, and
890 amino acids (aa) for human PKD1, -2, and -3, respectively). PKD1 and PKD2 are most
homologous and may originate from a common ancestor [5]. PKDs are widely distributed
in the body, although their relative expression varies with different organs, with PKD1 and
PKD2 being more prevalent in the lung, brain, kidney, heart, smooth muscle, pancreas,
and prostate, and with PKD3 being more ubiquitous [1–4,6]. The conserved structure of
PKD contains a N-terminal regulatory region that mainly comprises a C1 domain and a
pleckstrin homology (PH) domain, followed by a C-terminal catalytic domain. The C1
domain constitutes two cysteine-rich Zn-finger-like motifs, Cla and Clb, that bind DAG
and phorbol esters, the pharmacological analogs of DAG, with high affinity and regulate
PKD localization to the nucleus, Golgi, and plasma membrane [7,8]. The PH domain exerts
an autoinhibitory function on the catalytic domain to keep the kinase inactive at basal
state [9,10]. Additionally, the regulatory domain contains an alanine–proline rich (AP)
region at the N-terminus for PKD1 and a proline-rich (P) region for PKD2, and an acidic
amino-acid-rich region (AD) between Clb and PH domains, and the functions of these
domains remain obscure [11]. Recently, a ubiquitin-like domain (ULD) shared by all three
PKD isoforms was identified at the N-terminus following the AP or P region. Based on the
X-ray crystal structure of the ULD-C1a domain in the C. elegans PKD homolog DKF-1, ULD
may act to initiate PKD dimerization at the membrane for trans-autophosphorylation at
the activation loop in response to increased DAG concentration, leading to PKD activation
possibly independent of PKC [5,12]. This domain appears to be conserved in all three
human PKD isoforms [5,12]. The structure of PKD1 and PKD2 also contains a C-terminal
PDZ domain that is thought to facilitate protein substrate recognition [7]. Within the PDZ
domain, there is an autophosphorylation site (S910 for PKD1, S876 for PKD2), which is
commonly used as a measure for PKD activation status, although its phosphorylation likely
also plays a functional role [7,13,14] (see Figure 1 for a schematic diagram of human PKD1,
-2, and -3).
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Figure 1. A diagram illustrating the conserved structural domains and major phosphorylation sites in human protein 
kinase D (PKD) isoforms. The structure of PKD contains a newly identified ubiquitin-like domain (ULD) for dimerization, 
a C1 domain (Cla and Clb) that binds diacylglycerol, a pleckstrin homology (PH) domain for autoinhibition, a catalytic 
domain for substrate phosphorylation, and a PDZ domain in PKD1 and PKD2 for protein interactions. Other domains 
with less known functions are the acidic amino-acid-rich region (AR) and an alanine–proline-rich region (AP) for PKD1 
and a proline-rich region (P) for PKD2. Major phosphorylation sites and the upstream kinases that confer the phosphory-
lation are indicated as well as the nuclear export signal (NES) and nuclear localization signal (NLS) for PKD2. Abbrevia-
tions: trans-Golgi network (TGN), Abelson murine leukemia viral oncogene homolog 1 (Abl), casein kinase 1 (CK1). 
2.2. Mechanisms of Regulation 
PKD can be activated downstream of GPCRs or receptor tyrosine kinases (RTKs) by 
a variety of stimuli such as hormones, growth factors, neuropeptides, lipids, and cellular 
stresses [7]. In a canonical activation pathway, following receptor stimulation, phospho-
lipase Cs (PLCs) are activated to hydrolyze phosphatidylinositol 4,5-biphosphate (PIP2) 
to generate inositol 1,4,5-trisphosphate (IP3) and DAG. IP3 mobilizes internal calcium and 
DAG along with calcium (for cPKC) binds and anchors classic or novel protein kinases C 
(c/nPKC) to the plasma membrane and triggers their activation. DAG also recruits cyto-
solic PKD to the plasma membrane by binding to its C1 domain; this process may induce 
a conformational change that allows PKC to colocalize with PKD at the plasma membrane 
to transphosphorylate a conserved serine residue (Ser738 for PKD1, Ser706 for PKD2, Ser731 
for PKD3) in the activation loop of PKD, leading to the autophosphorylation of an adjacent 
serine residue (Ser742 for PKD1, Ser710 for PKD2, and Ser735 for PKD3) and relief of autoin-
hibition by the PH domain for full activation of the kinase [15–17]. Given the lack of crystal 
structure of PKD, there remain many questions regarding the exact sequence of events 
occurring during the activation of PKD by DAG and PKC, particularly in light of the dis-
covery of a N-terminal ULD domain (see detailed discussion in ref. [5]). 
PKD can be activated at multiple subcellular locations and can also be mobilized to 
different cellular compartments to carry out unique functions at each site (Figure 2). PKD 
was first identified as a trans-Golgi network (TGN)-resident enzyme [18]; a series of land-
mark studies by the Malhotra group shows that PKD plays a critical role in regulating the 
fission of transport carriers from TGN to the cell surface [19–21]. As with its activation at 
the plasma membrane, PKD is recruited by DAG to the TGN [22]. An intact C1a domain 
and the catalytic activity of PKD are both required for its binding and regulation of vesicle 
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(Cla and Clb) that binds diacylglycerol, a pleckstrin homology (PH) domain for autoinhibition, a catalytic domain for
substrate phosphorylation, and a PDZ domain in PKD1 and PKD2 for protein interactions. Other domains with less known
functions are the acidic amino-acid-rich region (AR) and an alanine–proline-rich region (AP) for PKD1 and a proline-rich
region (P) for PKD2. Major phosphorylation sites and the upstream kinases that confer the phosphorylation are indicated as
well as the nuclear export signal (NES) and nuclear localization signal (NLS) for PKD2. Abbreviations: trans-Golgi network
(TGN), Abelson murine leukemia viral oncogene homolog 1 (Abl), casein kinase 1 (CK1).
2.2. Mechanisms of Regulation
PKD can be activated downstream of GPCRs or receptor tyrosine kinases (RTKs)
by a variety of stimuli such as hormones, growth factors, neuropeptides, lipids, and
cellular stresses [7]. In a canonical activation pathway, following receptor stimulation,
phospholipase Cs (PLCs) are activated to hydrolyze phosphatidylinositol 4,5-biphosphate
(PIP2) to generate inositol 1,4,5-trisphosphate (IP3) and DAG. IP3 mobilizes internal calcium
and DAG along with calcium (for cPKC) binds and anchors classic or novel protein kinases
C (c/nPKC) to the plasma membrane and triggers their activation. DAG also recruits
cytosolic PKD to the plasma membrane by binding to its C1 domain; this process may
induce a conformational change that allows PKC to colocalize with PKD at the plasma
membrane to transphosphorylate a conserved serine residue (Ser738 for PKD1, Ser706 for
PKD2, Ser731 for PKD3) in the activation loop of PKD, leading to the autophosphorylation
of an adjacent serine residue (Ser742 for PKD1, Ser710 for PKD2, and Ser735 for PKD3) and
relief of autoinhibition by the PH domain for full activation of the kinase [15–17]. Given the
lack of crystal structure of PKD, there remain many questions regarding the exact sequence
of events occurring during the activation of PKD by DAG and PKC, particularly in light of
the discovery of a N-terminal ULD domain (see detailed discussion in ref. [5]).
PKD can be activated at multiple subcellular locations and can also be mobilized
to different cellular compartments to carry out unique functions at each site (Figure 2).
PKD was first identified as a trans-Golgi network (TGN)-resident enzyme [18]; a series of
landmark studies by the Malhotra group shows that PKD plays a critical role in regulating
the fission of transport carriers from TGN to the cell surface [19–21]. As with its activation
at the plasma membrane, PKD is recruited by DAG to the TGN [22]. An intact C1a
domain and the catalytic activity of PKD are both required for its binding and regulation
of vesicle trafficking at the TGN [20,23]. The regulation of the TGN by PKD is essential
for many important secretory processes, and the best known is the regulation of insulin
secretion from pancreatic β cells [24] A well characterized substrate of PKD at the TGN is
phosphatidylinositol-4 kinase IIIβ (PI4KIIIβ). Phosphorylation and activation of PI4KIIIβ
is critical for protein transport at the TGN [25].
Following its activation at the plasma membrane, activated PKD can shuttle in and
out of the nucleus to regulate the activity and availability of several transcription factors.
Nuclear localization of PKD is regulated by more than one region of the domain structure,
and the precise export and import mechanisms for each isoform may vary with the specific
isoform and cellular context. In unstimulated cells, PKD1 and PKD2 exist primarily in
the cytoplasm, while PKD3 is present in both the nucleus and cytoplasm as a result of
continuous shuttling [26]. In earlier studies, it was shown that the Clb motif controls
the nuclear import of PKD1, with evidence supporting the use of a nonclassical nuclear
localization signal (NLS). The nuclear export of PKD1 is regulated by the PH domain in
a Crm-dependent manner [27]. A recent study identified a complex formed between the
catalytic domain of PKD1 and Hsp20, which is essential for PKD1 nuclear translocation
and downstream signaling events leading to cardiac hypertrophy [28]. This supports a
potential complex and cell context-dependent regulation of PKD1 nuclear localization. For
PKD2, an isoform that has been more extensively studied in this aspect, the C-terminus
of C1a and the linker region between Cla and Clb contains a putative bipartite NLS (key
residues 192RKRR195), which is critical for the nuclear import of PKD2, while Cla contains
a functional nuclear export signal (NES) that is required for the nuclear export of PKD2 [29]
(Figure 1). Interestingly, the nuclear location of PKD2 can be regulated by a casein kinase
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1-mediated S244 phosphorylation in the C1a/C1b linker region of PKD2 [30]. For the
nuclear import of PKD3, it appears that the catalytic activity of the kinase is essential,
implying the involvement of other import partners, and the export is similarly dependent
on Crm1 [26,31].
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Figure 2. Schematic representation of signaling pathways and pathological processes regulated by PKD. The schematic
representation shows the pathways that activate PKD and the various downstream signaling events and functions modulated
by the kinase. PKD can be activated through stimulating various membrane receptors such as G-protein-coupled receptors
(GPCRs) and growth factor receptors. The extracellular stimuli activate phospholipase C (PLC), which catalyzes the
formation of diacylglycerol (DAG). DAG modulates PKD activation by binding and recruiting it to the cell membrane
for activation by protein kinase C (PKC). PKD can also be activated on the outer itochondrial membrane by oxidative
stress thr ugh binding to DAG and PKC. Activated PKD is rapidly t anslocated from the pl sma membrane to the cytosol
and then to the nucleu , where it regulates a set f transcription factors in the nucleus. Activated PKD regulates a battery
of pathological processes including cell proliferation, survival, migration, invasion, gene transcription, inflam ation,
angiogenesis, and secretion of tumor-associated factors through several major signaling pathways. Abbreviations: matrix
metalloproteinase (MMP), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), insulin-like
growth factor (IGF), metastasis-associated 1 (MTA1), slingshot-1L (SSH1L), GPCR kinase-interacting protein 1 (GIT1).
PKD can also be activated in response to an increase in mitochondrial or cellular reac-
tive oxygen species (ROS). Work by the Toker and Storz groups shows that increased ROS
induces several tyrosine phosphorylations in PKD1 (Tyr95, Tyr432, Tyr463, and Tyr502) [32–34].
Furthermore, Abelson murine leukemia viral oncogene homolog 1 (Abl) directly phospho-
rylates PKD at Tyr463 in the PH domain to initiate a conformational ch nge which allows
PKD1 to translocate to the mitochondrial membrane through binding t DAG, whic is
generated by activated phospholipase D1 dow stream of mitochondrial ROS [35]. Phos-
ph rylation of PKD1 at Tyr95 by pr to- ncogene tyrosine kinase Src then allows PKCδ to
bind and fully activate PKD1 via activatio loop ph sphorylation. PKD1 then induces the
activati n of the Nuclear Factor-κB (NF-κB) signaling pathway to prom te cell survival and
d toxif catio of mitochon rial ROS via induction of manganese-dependent superoxide
dismutase (MnSOD) [33,34,36]. In rec nt years, isoform- a d c ll context-specific regulation
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of ROS-induced PKD activation has been observed along with downstream signaling events.
Detailed discussions on this topic can be found in three reviews (see references [13,37,38]).
3. PKD in Pathological Processes and Human Diseases
Emerging evidence indicates that PKD is involved in the regulation of a battery of
cellular and pathophysiological conditions linked to a variety of human diseases, such
as cancer [6,7], cardiovascular diseases [13,16], inflammatory diseases [39,40], and so on.
Here, we have summarized recent studies on the signaling mechanisms and functional
involvement of PKDs in major human health conditions, highlighting the key signaling
proteins regulated by PKD in each pathological condition (Figure 3).
Biomolecules 2021, 11, x FOR PEER REVIEW 6 of 33 
 
 
Figure 3. Versatile roles of PKD in human diseases. Schematic representation of key roles and major signaling targets of 
PKD in the pathogenesis of cancer and other human diseases. Abbreviations: central nervous system (CNS), epithelial-to-
mesenchymal transition (EMT), natural killer (NK) cell, Toll-like receptor (TLR), nuclear factor of activated T cells 
(NFATs), sterol regulatory element binding protein (SREBP). 
3.1. Cancer 
PKD and its downstream targets are linked to the development and progression of 
human cancers, including those of the prostate, breast, pancreas, skin, stomach, etc. PKD 
has been extensively studied in multiple cancer relevant pathological processes. Our re-
view will focus on the impact of PKD in pathways pertinent to several hallmarks of cancer, 
including enhanced growth, proliferative capacity [6,7,39,41,42], evasion of cell death 
[6,43–45], migration and invasion [41,42], angiogenesis [46,47], and immune modulation 
[6,48–50]. The role of each PKD isoforms in each of the pathological process will be re-
viewed and discussed (see a summary on the contributary roles of PKD isoforms in cancer 
in Table 1). 
Figure 3. Versatile roles of PKD in human diseases. Schematic representation of key roles and major signaling targets of
PKD in the pathogenesis of cancer and other human diseases. Abbreviations: central nervous system (CNS), epithelial-to-
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3.1. Cancer
PKD and its downstream targets are linked to the development and progression
of human cancers, including those of the prostate, breast, pancreas, skin, stomach, etc.
PKD has been extensively studied in multiple cancer relevant pathological processes.
Our review will focus on the impact of PKD in pathways pertinent to several hallmarks
of cancer, including enhanced growth, proliferative capacity [6,7,39,41,42], evasion of
cell death [6,43–45], migration and invasion [41,42], angiogenesis [46,47], and immune
modulation [6,48–50]. The role of each PKD isoforms in each of the pathological process
will be reviewed and discussed (see a summary on the contributary roles of PKD isoforms
in cancer in Table 1).









- Stimulates accumulation of c-Fos,
DNA synthesis via strengthening
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β-catenin [61]
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A kinase at the centrosome
[63]
- Colon - Stimulates NF-κB activity via AKTand ERK signalling [64]
- Glioblastoma - Regulates Golgi phosphoprotein 3 [65]
PKD3 Positive
- Breast - Regulates mTORC1-S6 kinase 1signalling [66]
- Activates ERK1/c-Myc axis [67]
- Phosphorylates HSP27 and
HDAC4/5/7 [68]





Function Cancer Types Target Gene/Mechanisms Ref
Survival
PKD1 Positive
- Pancreatic - Activates glucose transporter 1and mTORC1 [69]
- Induces anti-apoptotic proteins
survivin and c-FLIPL
[70]
- Prostate - Activates ERK1/2 and NF-κBsignalling [8]
PKD2 Positive
- Prostate; Colon;
Leukemia - Stimulates NF-κB activity [8,71,72]
- Colon; Breast - Reverses HSP90inhibition-induced apoptotic effects [45]




- Prostate; Breast - Inactivates transcription factorSnail [74,75]
- Prostate - Phosphorylates junctionalproteins (E-cadherin and β-catenin) [76,77]
- Polyubiquitination and
proteasomal degradation of MTA1 [78]
- Breast - Promotes Avβ3 integrin recyclingvia phosphorylating Rabaptin-5 [79]
- Represses the expression of MMPs [80]
- Melanoma - Phosphorylates SSH1L, blockcofilin dephosphorylation [81]
- Regulates E-cadherin expression
and β-catenin localization [82]
PKD2 Positive
- Prostate
- Phosphorylates IKKβ, nuclear





- Stimulates expression and
secretion of MMP-7 and MMP-9 [84]
- Liver - Regulates MMP-1 and integrinexpression [85]
- Prostate - Promotes PI3K/Akt/GSK-3βsignalling [86]
PKD3 Positive
- Breast - Activates NFκB and deactivateHDAC1 [83]
- Secretion of MMP-9 and
tumor-promoting cytokines [87]
- Activates PAK4/LIMK signaling [88]
- Regulates cytoskeletal remodeling
by phosphorylating GIT1 [89]
Angiogenesis
PKD1 Positive
- Pancreatic - Induces the secretion of VEGF andCXC chemokines [90]
- Breast - LPA/PKD-1-CD36 signaling [91]
PKD2 Positive
- Gastrointestinal - Regulates tumor-endothelial cellcommunication [92]
- Colon; Breast - Stabilizes Hsp90; NF-κB/VEGF-A [44,45]
PKD3 Positive - Prostate - Regulates mast cell recruitment [47]









- Oral squamous - Regulates PD-L1 surfaceexpression [93]
- Fibrosarcoma - Phosphorylates and degradesIFNAR1 [94]
PKD3 Positive - Oral squamouscell carcinoma
- Regulates IFN-γ induced PD-L1
expression [50]
3.1.1. Cell Growth and Proliferation
Uncontrolled proliferation is one of the most relevant hallmarks of cancer that leads
to the formation of a tumor mass. PKD regulates cell proliferation in a variety of cellular
systems. It was the earliest biological function characterized for PKD [95,96]. Pioneered by
the Rozengurt group, it has been shown that a large number of mitogenic GPCR agonists,
such as bombesin, vasopressin, endothelin, and bradykinin, can activate PKD1 through
Gq and G12, leading to enhanced cell proliferation [95,97–102]. The downstream effectors
include the class IIa histone deacetylases (HDACs) [103] and the β-catenin transcription
factor [104]. Cell proliferation is controlled through regulation of the cell cycle. PKD has
been identified as a novel cell cycle regulator at the G2–M and mitotic phase of the cell
cycle in normal cells [105–108]. We have reported that PKD2 is activated during G2–M and
that inactivation or depletion of PKD2 delays mitotic entry by inducing Aurora A kinase
degradation [63]. Mechanistically, PKD2 colocalizes with Aurora A at the centrosome by
binding to γ-tubulin, and knockdown of PKD2 causes defects in centrosome separation,
an elongated G2 phase, mitotic catastrophe, and eventually cell death via apoptosis [63].
In line with our study, Kienzle et al. reported that knockdown of PKD1 and PKD2 leads
to accumulation of cells in the G2 phase of the cell cycle and prevents cells from entering
mitosis by blocking mitotic Golgi fragmentation via the Raf–MEK1 signaling pathway [106].
The Rey group reported that during mitosis, both PKD1 and PKD3 become phosphorylated
in their activation loop at Ser744 and Ser731, respectively, in a PKC-dependent manner [105].
Further analysis revealed that all three activation loop-phosphorylated PKDs associated
with the mitotic apparatus, including centrosomes, spindles, and midbodies [105]. PKD1
inhibition during mitosis results in formation of abnormal spindles, defects in chromosome
alignment, and segregation, indicating that PKD1 activation is required for mitotic cell
cycle transition [108]. The regulation of G2 and M implies that PKD may be a valuable
target for inhibition of cancer cell proliferation. Indeed, depletion or inhibition of PKD
has been shown to induce G1 or G2–M cell cycle arrest in a variety of cancer cells. For
example, we have shown that depletion of PKD2 causes accumulation of cells in G2–M
and delays the mitotic entry of prostate cancer cells [63]. We and others have also shown
that the inhibition of PKD by multiple small-molecule inhibitors blocks prostate cancer cell
proliferation by arresting cells in the G2–M phase of the cell cycle [55,56,64,109]. Similarly,
abrogation of PKD2 induces G2–M arrest in lung adenocarcinoma cell lines [110]. Besides
the regulation at G2–M, PKD2 abrogation could also induce G1 arrest of glioblastoma cells,
correlating with the downregulation of cyclin D1 [111].
Beyond cell cycle regulation, MEK/extracellular-regulated protein kinase (ERK) is a
major signaling hub through which PKD regulates tumor cell proliferation [53,54,57,58].
In particular, PKD1 has been shown to mediate neurotensin (NT)-induced cell prolifera-
tion by suppressing JNK/c-Jun activation and increasing the duration of NT-stimulated
ERK activation in pancreatic cancer cells, resulting in the accumulation of c-FOS, DNA
synthesis, and proliferation of pancreatic carcinoma cells [51]. PKD1 overexpression also
promoted GPCR agonists bombesin and gastrin-releasing peptide-induced ERK1/2 activity
and potentiated bombesin-stimulated tumor cell proliferation in head and neck squamous
cell carcinoma [53]. Accordingly, pharmacological inhibition of PKD or PKD2 knockdown
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in colon cancer cell lines blocked Akt and ERK signaling and suppressed NF-κB activity,
leading to G2–M arrest and induction of apoptosis in vitro along with reduced tumor
growth in vivo [64]. PKD2, on the other hand, was shown to inhibit glioma cell prolifera-
tion by upregulating Golgi phosphoprotein 3 (GOLPH3) and inducing Akt activation [65].
PKD3 supports the proliferation of triple-negative breast cancer cell proliferation through
mammalian target of rapamycin complex 1 (mTORC1)-S6 kinase 1 and the subsequent
autophagic pathway [66]. Beyond the regulation of major signaling molecules, PKD also
regulates transcription factors that are critical for tumor cell proliferation, such as c-MYC
and class IIa HDACs [67,68]. Deletion of PRKD3 by CRISPR/Cas9 in breast cancer cell
lines suppressed phosphorylation of ERK1 and c-MYC and led to reduced cell prolifer-
ation in vitro and tumor growth in vivo [67]. Silencing PKD2 or PKD3 also significantly
blocked HCC1806 triple-negative breast cancer cell proliferation, and in particular, PKD3
knockdown inhibited Hsp27 and HDAC4/5/7 phosphorylation [68]. Thus, PKD1–3 have
all been reported to promote tumor cell growth and proliferation through both shared and
distinctive signaling pathways.
Although most studies support a pro-proliferative role of PKD in various biological
systems, some have shown an opposite antiproliferative function of PKD1 in several can-
cers, including prostate [59,77], lung [62], and colon [61] cancer. PKD1 expression was
shown to be downregulated in higher-grade colon cancer compared with non-neoplastic
samples [61], and overexpression of PKD1 in human SW480 colorectal cancer cells inhib-
ited cell proliferation, clonogenicity, and delayed tumor growth in a xenograft mouse
model [61]. The antiproliferative effect was mediated through PKD1-induced nuclear
exclusion of β-catenin and the subsequent decrease of its transcriptional activity [61].
Additionally, PKD1 was also found to be downregulated in non-small cell lung cancer
patients with venous invasion or lymph node metastasis and loss of PKD1 enhanced the
malignant potential of the tumor cells, possibly by negative regulation of mTORC1–S6K1
signaling [62]. Similarly, the Balaji group reported that PKD1 expression was reduced in
metastatic prostate cancer samples but not in benign and primary tumor samples [59]. The
authors also demonstrated that PKD1 interacts with β3 integrin to activate ERK signal-
ing, which leads to increased secretion of matrix metalloproteinase (MMP)-2 and MMP-9,
therefore suppressing prostate cancer cell proliferation as well as colony formation [59]. A
later study by the same group showed that overexpressing PKD1 in prostate, breast, and
colon cancer cell lines led to accumulation of cells in G1 phase, which may be mediated
through the direct phosphorylation of all three cell-division cycle 25 proteins (Cdc25s) (A,
B, and C) by PKD [60]. The antiproliferative effect of PKD could also be mediated through
the binding of PKD1 with β-catenin and the subsequent inhibition of β-catenin-mediated
proliferation [77]. Interestingly, PKD1 can also be repressed by oncogenes, providing a
molecular basis for its downregulation. Specifically, it was found that nuclear β-catenin
could recruit MYC and its obligate heterodimer MAX to form a transcription complex,
which repressed PRKD1 expression by binding to the promoter [112]. Taken together, there
is compelling evidence that PKD1 could repress cell proliferation in certain tumor types,
although the underlying molecular mechanisms are not fully understood.
Several genetically modified mouse models were developed to study PKD1 involve-
ment in tumor initiation and progression in vivo. The Storz group generated a conditional
PKD1 knockout mouse model to study the role of PKD in the initiation of pancreatic
cancer [52]. In transgenic KC mice (p48cre; KrasG12D), expression of active KrasG12D in
pancreatic cells can drive the formation of acinar-to-ductal metaplasia (ADM) and further
the progression to pancreatic intraepithelial neoplasia (PanIN). It was found that PKD1
expression was upregulated in regions of ADM and in PanINs in these transgenic mice [52].
By crossing PKD1 knockout (PKD-/-) mice with the KC mice, the authors generated acinar
cell-specific PKD1-knockout KC mice (p48cre; KrasG12D; PKD1-/-), which showed that
loss of PKD1 in pancreatic acinar cells significantly decreased active KrasG12D-induced
formation of PanIN lesions [52]. These results revealed a functional role of PKD1 in driving
ADM reprogramming and progression to PanINs. In another study by the Ghazizadeh
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group, mice with epidermis-targeted PKD1 deletion were generated and displayed a
normal skin phenotype, indicating that PKD1 is dispensable in skin development and
homeostasis [41]. However, when the dorsal skin was wounded, PKD1-knockout mice
displayed delayed wound re-epithelialization, reduced proliferation, and migration of
keratinocytes at the wound edge compared to the control mice [41], implying a potential
critical pro-proliferative role for PKD1 in skin carcinoma. The Balagi group also generated
a prostate-specific PKD1-knockout and a phosphatase and tensin homolog (PTEN)/PKD1
double-knockout mouse line with expression of different fluorescent proteins (Prorainbow
mouse) for the purpose of cell lineage tracing in both normal and malignant prostate
development [113]. The authors commented that the PKD1-knockout Prorainbow mice
presented normal prostate size and pathological phenotype similar to those of control
littermates [113], indicating that loss of PKD1 did not impact prostate development. How-
ever, the in vivo tumor-suppressive function of PKD1 in prostate cancer, particularly in the
PTEN/PKD1 double-knockout mice, has not been reported.
The seemingly opposing effects of PKD1 on cell proliferation in different cancer cells
are both interesting and intriguing, suggesting that other unknown factors or the cellular
environment may alter the behaviors of PKD1 in cancer cells. Certainly, these discrepancies
could also be explained by the use of different experimental systems, reliability of anti-
bodies in detecting PKD expression and activity, and limited tissue samples examined, etc.
Many of these studies rely on overexpression of PKD1 in cells, which could be problematic
and requires further validation using other more physiological approaches. The lack of
animal models to verify the function of PKDs in vivo is also a major drawback in the
current state of PKD research in cancer.
3.1.2. Cell Survival and Apoptosis
Besides uncontrolled tumor cell growth, evasion of programmed cell death (apoptosis)
is another major driving force of tumor progression. All three PKDs have been reported
to promote tumor cell survival. The major pathways through which PKD promotes tu-
mor cell survival are NF-κB [8,72], ERK1/2 [64,73], Akt [64,73], and heat shock protein 90
(HSP90) [45] signaling. PKDs are known to protect cells from oxidative stress-induced cell
death by activating the NF-κB transcription factor [34]. The production of reactive oxygen
species at the mitochondria results in tyrosine phosphorylation of PKD at Tyr463 in the PH
domain [34]. PKD then activates NF-κB and induces MnSOD to promote cell survival, as
described above [34,36]. PKD2 protects tumor cells from apoptotic cell death by activating
NF-κB signaling in several cancers [8,71,72]. For example, in human myeloid leukemia
cells, PKD2 is constitutively tyrosine-phosphorylated by the oncogenic Bcr–Abl fusion
protein, a driver of chronic myeloid leukemia and a mediator of Bcr–Abl-induced NF-κB
activation [72]. In colon cancer cells, PKD inhibition in combination with regorafenib (an
oral multikinase inhibitor with antiangiogenic activity) resulted in enhanced apoptosis
through downregulating ERK, AKT, and NF-κB signaling activities [71]. Besides NF-κB
signaling, PKD also regulates the expression of other prosurvival proteins. In pancreatic
adenocarcinoma cells, PKD1 expression correlated with resistance to CD95-induced apopto-
sis and promoted cell survival through the induction of the antiapoptotic proteins survivin
and c-FLIPL [70]. In prostate cancer cells, PKD2 played an antiapoptotic role in phorbol
ester-induced apoptosis in androgen-sensitive prostate cancer cells through the ERK1/2
and NF-κB pathways [8]. Furthermore, PKD2 interacted with and was stabilized by the
HSP90 chaperone protein in several human cancer cell lines to support tumor survival [45].
Specifically, both short hairpin RNA (shRNA)-mediated abrogation of HSP90 isoforms
(HSP90A and HSP90β) and pharmacologic inhibition of HSP90 by PU-H71 and STA-9090
resulted in decreased PKD2 protein levels and enhanced apoptosis in lung, pancreatic,
and breast cancer cell lines [45]. Conversely, ectopic expression of PKD2 protected cancer
cells from HSP90 inhibition-induced apoptotic effects in two in vivo mouse models [45].
In addition, increased PKD3 expression and PKD3 nuclear accumulation were found
in androgen-independent prostate cancer cell lines compared with androgen-dependent
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LNCaP cells [73]. Overexpression of PKD3 in LNCaP cells blocked phorbol ester-induced
apoptosis and also inhibited phorbol ester-induced downregulation of Akt activity, demon-
strating the prosurvival effects of PKD3 [73]. Taken together, members of the PKD family
in general promote tumor cell survival by activating major survival pathways, such as the
NF-κB signaling pathway, to evade apoptosis induced by cellular stresses.
Cytotoxic chemotherapy drugs induce apoptotic cell death in cancer cells to prevent
tumor progression. One of the major obstacles for chemotherapeutic treatment in human
cancers is the development of drug resistance. PKDs have been implicated in the develop-
ment of drug resistance in multiple cancers. PKD1 overexpression enhanced cell viability
and resistance to gemcitabine through activating glucose transporter 1 and mTORC1 to
increase metabolic adaptation in pancreatic cancer cells [69]. Furthermore, PKD2 was
identified as an important regulator of drug resistance and P-glycoprotein expression in
paclitaxel-treated breast cancer cells [114]. Knockdown of PKD2 in these cells resulted in
a significant decrease in resistance to paclitaxel treatment [114]. In addition, PKD3 was
identified as a valid target to overcome drug resistance against RAF and MEK inhibitors
in melanoma cell lines [115]. Although this area of research remains sparse, current find-
ings support targeted inhibition of PKD as a potential strategy to overcome therapeutic
resistance in cancer.
3.1.3. Cell Adhesion, EMT, Migration, and Invasion
The epithelial-to-mesenchymal transition (EMT) is a biological process by which ep-
ithelial type cells lose their polarization and cell–cell adhesion through cytoskeleton reor-
ganization and undergo distinct biochemical changes to become mesenchymal-type cells
with enhanced migratory and invasive properties [116]. A hallmark for EMT is the loss of
E-cadherin, a transmembrane protein that mediates cell–cell adhesion in epithelial cells. Neg-
ative regulation of CDH1, the gene that encodes E-cadherin, by transcription factors Snail,
Slug, ZEB1, and ZEB2 resulted in the loss of E-cadherin [117]. E-cadherin exerted its antipro-
liferative, anti-invasive, and antimetastatic properties through binding to β-catenin to form
a protein complex and interacting with the actin and microtubule cytoskeleton [117,118].
Multiple lines of evidence have indicated that PKD could regulate EMT through modulating
the E-cadherin/β-catenin complex and EMT regulatory transcription factors in epithelial
cells. The Storz group demonstrated that PKD1 was expressed constitutively in murine
mammary gland epithelial cells and prevented transition to a mesenchymal phenotype [119].
The authors show that PKD1-mediated phosphorylation of Snail, a transcriptional repressor
of E-cadherin, at Ser11 reduced the ability of Snail to bind to its corepressor protein Ajuba,
and therefore inhibited the ability of Snail to repress E-cadherin expression and consequently
blocked EMT [119].
Cells that have undergone EMT due to loss of E-cadherin display enhanced motility,
a process that requires concerted regulation of multiple cellular events including actin
cytoskeletal remodeling. During migration, cells move with extending protrusions at
the leading edge and a retracting tail at the rear; both are associated with actin remod-
eling events which are regulated by a group of actin-related proteins such as cofilin,
vasodilator-stimulated phosphoprotein (VASP), profilin, and actin-related protein-2/3
complex (ARP2/3) [120,121]. Cell migration is achieved when the actin-binding protein
cofilin slices actin filaments at the leading edge of motile cells, generating a supply of actin
monomers, and orchestrating the formation of WAVE-2–cortactin–ARP2/3 complex, which
ultimately creates an expanded, branched network of F-actin [120]. Cofilin can be inacti-
vated through phosphorylation at Ser3 by kinases such as LIM domain kinase 1 (LIMK1)
(because it can no longer bind to actin), and cellular migration is suppressed when cofilin
is phosphorylated, whereas cell motility is restored through cofilin dephosphorylation by
phosphatases such as slingshot protein phosphatase 1L (SSH1L) [122,123]. Studies by the
Storz group show that overexpression of constitutively active PKD1 significantly decreased,
whereas overexpression of inactive mutants of PKD1 increased cell migration [124]. In
another study, they further demonstrated that PKD1 phosphorylated SSH1L at Ser978 in its
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actin-binding motif, which then generated a 14-3-3 binding motif that blocked localization
of SSH1L to F-actin in the lamellipodium, blocking cofilin dephosphorylation and thereby
inhibiting cell migration [124]. PKD1 also regulated cofilin activity by phosphorylat-
ing/activating p21-activated kinase 4 (PAK4), an upstream protein kinase for LIMK1 [125].
Activation of PAK4/LIMK1 signaling led to the accumulation of phosphorylated inactive
cofilin in cells and consequently blocked cell migration [125]. Besides the regulation of
cofilin, PKD1 also blocked cell migration through phosphorylating the Ras effector protein
Rab interactor 1 (RIN1) at Ser292, a phosphorylation site that controls the RIN1-mediated
inhibition of cell migration by modulating Abl kinases’ activation [126]. Moreover, PKD1 in-
hibited cell motility through regulating focal adhesion dynamics and filopodium formation,
which are mediated through the phosphorylation of phosphatidylinositol-4-phosphate
5-kinase type-1γ (PIP5K1γ) [127] and VASP, respectively [128].
During the tumorigenic process, PKD1 is thought to function by maintaining the
epithelial phenotype, while malignant cells gain motility by downregulating PKD1 expres-
sion [14,42,82,129]. PKD1 negatively regulates cancer cell motility through multiple mecha-
nisms including inactivating transcription factor Snail [74,75], phosphorylating adherens
junctional proteins (E-cadherin and β-catenin) [76,77] and metastasis-associated protein
1 (MTA1) [78], regulating integrin trafficking [79], stabilizing F-actin filaments at leading
edges and filopodia [81,88,124–126,128], and repressing the expression of MMPs [80]. In
prostate and breast cancer cells, PKD1 phosphorylated Snail, resulting in the nuclear export
and proteasomal degradation of Snail and subsequent inhibition of EMT [74,75]. In addition
to transcriptional regulation of E-cadherin, PKD1 also phosphorylated E-cadherin directly.
Jaggi et al. showed that PKD1 interacted with E-cadherin at cell junctions in prostate cancer
cells [76]. More interestingly, phosphorylation of E-cadherin by PKD1 was associated with
increased cellular aggregation and decreased cellular motility in prostate cancer [76]. The
same group also demonstrated that PKD1 interacted with and phosphorylated β-catenin
and therefore controlled the formation of E-cadherin-mediated cell adhesion in epithelial
cells [77]. In a recent study, Ganju et al. identified another PKD1-interacting substrate,
metastasis-associated protein 1 (MTA1), in prostate cancer [78]. The authors showed that
PKD1 phosphorylated MTA1 and triggered polyubiquitination and proteasomal degra-
dation of MTA1, therefore inhibiting tumor cell migration and invasion [78]. The authors
further demonstrated a reverse correlation between PKD1 and MTA1 expression in a trans-
genic adenocarcinoma of the mouse prostate (TRAMP) model and in samples of human
prostate cancer, in which PKD1 expression decreased, whereas MTA1 expression increased
with progressed tumor stage [78]. Additionally, PKD1 promoted αvβ3 integrin recycling
through phosphorylating rabaptin-5 and inhibited both breast cancer and colorectal cancer
cell invasion into fibronectin-rich matrices [79]. In breast cancer cell lines, overexpression of
constitutively active PKD1 repressed tumor cell migration, whereas downregulating PKD1
led to increased cell migration [81,124]. For example, Philipp et al. showed that the loss
of PKD1 decreased cofilin phosphorylation and induced chemotactic migration of breast
cancer cells in an SSHL1-dependent manner [81]. PKD1 also regulated the expression of
MMPs, which are a class of proteases that mediate cell migration through extracellular
matrix (ECM) degradation. It was reported that PKD1 inhibited breast cancer cell invasion
by negatively regulating the transcription of several MMPs, including MMP-2, MMP-7,
MMP-9, MMP-10, MMP-11, MMP-13, MMP-14, and MMP-15 [80]. Taken together, PKD1 is
a negative regulator of EMT, cell migration, and invasion.
In contrast to PKD1, PKD2 and PKD3 appear to act in the opposite manner and posi-
tively regulate EMT and migration/invasion through multiple mechanisms involving the
regulation of cofilin [88], NF-κB and urokinase-type plasminogen activator (tPA) expres-
sion/activation [83], MMP and integrin expression [84,85,130,131], and the PI3K/AKT/
glycogen synthase kinase 3 beta (GSK-3β)/β-catenin pathway [86]. In fact, it has become
increasingly clear that PKD2 and PKD3, opposite to PKD1, associate with more malignant
cancer phenotypes and promote tumorigenesis and progression. Our earlier work has
demonstrated increased expression levels of PKD3 in human prostate cancer samples when
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compared to normal prostate tissues, and there was a correlation between PKD3 nuclear
localization and higher tumor grade [73]. Zou et al. showed that endogenous PKD2 inter-
acted with and phosphorylated IKKβ in invasive prostate cancer cells and was responsible
for the nuclear translocation and activation of the p65 subunit of NF-κB through phosphory-
lation of S276 on p65, whereas PKD3 was responsible for S536 phosphorylation on p65 and
deactivation of HDAC1 [83]. These PKD2- and PKD3-mediated signaling events coordi-
nated to promote prostate cancer cell invasion [83]. Our group investigated functional roles
of PKD3 in prostate cancer cell motility using both a stable inducible knockdown cell model
and a transient knockdown system via multiple small interfering RNAs (siRNAs) [87]. We
found that the silencing of endogenous PKD3 significantly reduced prostate cancer cell
migration and invasion [87]. Mechanistic studies indicated that depletion of PKD3 blocked
the secretion of MMP-9 and several tumor-promoting cytokines, such as IL-6, IL-8, and
GROα, without altering their mRNA levels [87] and that inducible depletion of PKD3 in a
subcutaneous xenograft model decreased levels of intratumoral GROα in mice [87]. Simi-
larly, PKD2 and PKD3, but not PKD1, were expressed in the highly metastatic breast cancer
cell lines MDA-MB-231 and MDA-MB-468 [88,130,132]. PKD3 was constitutively active in
MDA-MB-468 breast cancer cells under normal growth conditions, and this basal activity
was sufficient to stimulate PAK4/LIMK signaling without affecting SSH1L activity, which
contributed to a functional cofilin activity cycle and directed cell migration by activating
PAK4 [88]. In addition to regulating the cofilin cycle, PKD3 can also stimulate migration
through phosphorylating G-protein-coupled receptor kinase-interacting protein 1 (GIT1),
whose dynamic localization to sites of cytoskeletal remodeling was critical in the regulation
of cell spreading and migration [89]. In line with the studies on PKD3, Yasuhito et al.
showed that siRNA-mediated knockdown of PKD2 efficiently inhibited Matrigel invasion
of MDA-MB-231 cells [130]. A similar effect was observed in another breast cancer cell
line, in that siRNA-mediated knockdown of PKD2 inhibited migration of MCF7 cells [133].
Meanwhile, PKD2 knockdown in lung adenocarcinoma cell lines significantly reduced the
expression of mesenchymal markers (N-cadherin, vimentin) and the transcription factors
that stimulated EMT (Twist, Snail), along with inhibiting cell migration, invasion, and
proliferation, indicating that PKD2 promotes the EMT and metastatic potential of lung
adenocarcinoma [110]. In another study by the Seufferlein group, PKD2 was upregulated
in pancreatic cancer, and ectopic expression of PKD2 significantly enhanced invasion of
pancreatic cancer cells in the surrounding three-dimensional ECM through stimulating ex-
pression and secretion of MMP-7 and MMP-9 [84]. PKD2 has also been reported to promote
migration and invasion by regulating MMP-1 and integrin expression in glioblastoma [85].
In addition, PKD2 is upregulated in hepatocellular carcinoma (HCC) and is correlated with
the metastasis of HCC [86]. The authors demonstrated that PKD2 positively regulated
TNFα-induced EMT and invasion of HCC through promoting the PI3K/Akt/GSK-3β sig-
naling cascade [86]. Overall, in contrast to the negative regulation of EMT, migration, and
invasion by PKD1, PKD2 and PKD3 generally promote tumor metastasis by stimulating
EMT and tumor cell migration/invasion in many cancer types.
3.1.4. Angiogenesis
Angiogenesis, the growth of new capillary blood vessels from the pre-existing vascu-
lature, plays pivotal physiological roles in embryonic development, wound healing, tissue
regeneration, and placental development [134–136]. However, when dysregulated, it can
also contribute to oncogenic, ischemic, infectious, and inflammatory diseases [134,137].
Tumor development requires angiogenesis, which brings oxygen and nutrient supplies to
and metabolic wastes away from tumor cells.
The angiogenic response is strictly controlled by pro- and antiangiogenic molecules
including growth factors, MMPs, cytokines, and integrins [138,139]. Specifically, the major
signaling molecule that regulates angiogenesis is vascular endothelial growth factor (VEGF),
which is commonly found to be induced by hypoxia or oncogene signaling. VEGF then
signals through its cognate receptor VEGF receptor-2 (VEGFR-2) and induces downstream
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signals that stimulate endothelial cell survival, proliferation, migration, and differenti-
ation [140]. A recent study demonstrated that silencing PKD1 or PKD2 in endothelial
cells enhanced association of transcription factor AP2β with the VEGFR-2 promoter, de-
creasing VEGFR-2 transcription [141]. Emerging studies have shown that PKDs regulate
both hypoxia-induced VEGF secretion by tumor cells and VEGF-stimulated tumor angio-
genesis [46,90,92,141,142]. Overexpressing PKD1 in pancreatic cancer cells significantly
increased their secretion of the proangiogenic factors VEGF and CXC chemokines, and
thereby promoted anchorage-independent growth, invasion, and angiogenesis in human
pancreatic cancer [90]. The Ren group reported that diet-induced obesity could promote
breast tumor progression via lysophosphatidic acid/PKD-1 signaling-mediated angiogene-
sis [91]. PKD2 was a crucial mediator of hypoxia-induced VEGF-A expression and secretion
in pancreatic tumor cells and promoted tumor-driven blood vessel formation and tumor
growth in vitro and in vivo [92]. Because HSP90 bound and stabilized PKD2 in cancer cells,
inhibition of HSP90 led to degradation of PKD2, thereby indirectly impacting the proangio-
genic function of PKD2 under hypoxic conditions by blocking HIF1α accumulation and
NF-κB/VEGF-A signaling activity [44,45]. Additionally, both PKD2 and PKD3 have been
shown to contribute to mast cell recruitment and tumor angiogenesis in the prostate cancer
microenvironment [47]. However, in this study, the authors commented that depletion of
PKD2 or -3 had no effect on VEGF secretion from prostate cancer cells or mast cells; instead,
a role of PKD2 and PKD3 on the secretion of stem cell factor and chemokine ligand 5 and
C-C motif chemokine 11 expression was implicated in the response [47]. Overall, all three
PKDs have been shown to promote angiogenesis through multiple mechanisms with VEGF
as a major signaling hub. Therefore, inhibition of PKD may serve as a potential effective
way to interrupt tumor angiogenesis and block tumor progression.
3.1.5. Immune Responses in Cancer
PKD2 is the major PKD isoform expressed in human and mouse T and B lymphocytes,
thymocytes, and spleen cells [143]. Type 1 interferons (IFN-α/β) play a critical role in mod-
ulating the immune responses against infectious agents and tumors [94]. IFNα activated
PKD2 through tyrosine phosphorylation at Tyr438; this molecular event was also neces-
sary for efficient serine phosphorylation and degradation of IFNAR1 and consequently
restricted magnitude and duration of cellular responses to IFN-α/β [94]. Interestingly,
PKD2 was identified as an important regulator of programmed death ligand-1 (PD-L1)
surface expression downstream of IFN-γ in human oral squamous carcinoma cells [93].
Inhibition of PKD2 activation not only decreased PD-L1 expression, but also reduced drug
resistance in chemotherapy [93]. In a recent study, PKD3 was also found to regulate the
expression of PD-L1 induced by IFN-γ in oral squamous cell carcinoma [50]. These studies
imply that PKD may modulate the immune response of tumor cells, representing a novel
potential target in cancer immunotherapy.
3.2. Cardiovascular Diseases
PKD is an important modulator of stress signaling in the heart and regulates many
biological processes in cardiac myocytes, such as gene expression, cell survival, excitation-
contraction coupling, and metabolism [13]. PKD1 is activated in the heart in response to
hypertension, pressure overload, and chronic neurohormonal stimulation [144–147]. The
Olson group reported that cardiac-specific deletion of PKD1 diminished cardiac hypertro-
phy and improved cardiac function in response to pressure overload, chronic adrenergic
stimuli, or angiotensin II signaling in mice [146]. Mechanistically, PKD1 phosphorylated
class IIa histone deacetylases (HDAC4, -5, -7, -9) (known negative regulators of patholog-
ical cardiac remodeling through binding and transcriptional repression of the myocyte
enhancer factor-2 (MEF2) transcription factor) and triggered their nuclear export, resulting
in MEF2 derepression and cardiac remodeling [146]. In a separate study using a trans-
verse aortic constriction-induced cardiac hypertrophy mouse model, the authors found
that PKD1 contributed to cardiac hypertrophy through inhibiting AKT/mTOR regulated
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cardiac autophagy [144]. In addition, PKD1 can also phosphorylate endothelial nitric oxide
synthase and regulate vascular endothelial growth factor-mediated angiogenesis [13]. For
example, Aicart-Ramos et al. showed that PKD specifically phosphorylates recombinant
endothelial nitric oxide synthase on Ser1179, leading to its activation and a concomitant
increase in nitic oxide synthesis [148]. Moreover, inhibition of PKD in mice results in an
almost complete disappearance of the vascular endothelial growth factor-induced vasodi-
lation of the carotid artery [148]. Although PKD1 is by far the most abundant isoform in
the heart, PKD3 has also been reported to mediate glucose uptake and account for the
morphological and functional changes as seen during the development of cardiac hypertro-
phy driven by cardiac transcription factors [149,150]. Specifically, Li et al. demonstrated
that PKD3 is required for the upregulation of the cardiac transcription factors including
nuclear factor of activated T cells (NFATs), NK family of transcription factor 2.5 (Nkx2.5),
and GATA4, which drive cardiac hypertrophy [149]. Taken together, the abnormally acti-
vated PKD, by altering the transcriptomic landscape of the cardiomyocytes, drives cardiac
remodeling and represents an attractive potential therapeutic target to treat cardiovascular
diseases such as stress-induced cardiac hypertrophy and heart failure.
3.3. CNS Disorders
Establishing and maintaining neuronal polarity is of great importance for neuronal
signaling and function, and neuronal polarization is dependent on the reorganization of
trafficking from the trans-Golgi network to plasma membrane [151,152]. Both PKD1 and
PKD2 are known to specifically regulate basolateral membrane trafficking in polarized
epithelial cells and are important players in the generation of epithelial polarity. Yin et al.
demonstrated that PKD1 and PKD2, but not PKD3, modulated the polarized mode of
hippocampal neurons [153]. The authors reported that PKD1 and PKD2 siRNAs disrupted
polarized membrane trafficking and markedly increased the percentage of neurons with
multiple axons compared to transfections with control siRNAs. On the contrary, transfec-
tion with dominant-negative PKD3 had no effect on neuronal polarization [153]. Later
studies further confirmed that PKD1 regulated neuronal polarity through its activity in the
Golgi apparatus, which allows PKD1 to regulate the sorting, packaging, and targeting of
different proteins and suppress the endocytosis of dendritic membrane proteins [152,153].
PKD1 exerted these functions through phosphorylation of downstream effector proteins,
including the scaffold protein Kidins220 and polarity protein PAR-1 [154,155].
PKDs have been implicated in several neural developmental disorders. PKD2 was
reported in the pathogenesis of autism spectrum disorder (ASD) [156]. Matsumura et al.
found that PKD2 was expressed at a very high level in neural stem cells in the embryonic
cerebral cortex, and an ASD-associated de novo PRKD2 mutation decreased the autophos-
phorylation of PKD2, and thereby PKD2 activity and the activity of its downstream effector
kinase ERK1/2 [156]. The authors then concluded that ASD-associated PRKD2 mutations
can be a risk factor for ASD due to disrupting PKD2 cellular function [156]. Moreover,
PRKD2 deletion was found in Rett syndrome (RTT), another neurodevelopmental disorder
affecting the nervous, musculoskeletal, and gastroenteric systems [157–159]. Whole exome
sequencing and copy number variation analysis from a female child patient revealed a
~5 MB microdeletion at the long arm of the chromosome 14q12 region, which resulted
in the deletion of a single copy of brain-specific genes including PRKD1, FOXG1, and
NOVA1 [158]. However, it remains to be determined if the deletion of PRKD1 was causal to
the disease phenotypes. Collectively, these studies imply that PKDs are important players
in neurodevelopment and that the disruption of PKD expression or function may lead to
neurodevelopmental diseases.
PKD also exerts neuroprotective functions under different stress conditions such as
oxidative stress and cerebral ischemia, and both are major pathological causes for neurode-
generative diseases (Alzheimer’s, Parkinson’s, and Huntington’s diseases) and stroke [160].
Pose-Utrilla et al. reported that H2O2 treatment induced a short activation followed by a
sharp inactivation of PKD that was triggered by calcium influx in cultured cortical neu-
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rons, resulting in the loss of NF-κB signals and impeding neuronal survival [161]. PKD
is activated in ischemic stroke model [162]. Interestingly, heat-shock protein (HSP27), an
established target that is known to exert cytoprotection against cerebral ischemia-induced
apoptotic neuronal death [163], directly binds and is phosphorylated by PKD in neurons
in response to ischemic/reperfusion injury [162]. Inhibition of PKD abolished HSP27-
mediated neuroprotection against neuronal ischemic insult in a mouse model of transient
cerebral ischemia—tMCAO [162]. Collectively, these studies imply that stress-induced
activation of PKD is likely neuroprotective in pathological cerebrovascular diseases.
3.4. Metabolic Diseases
PKDs have been reported to play pivotal roles in metabolic regulation in various
tissues and organs such as the liver, adipose tissue, skeletal muscle, and pancreatic β
cells. PKD isoforms are well studied in the regulation of glucose homeostasis, insulin
secretion, and lipid metabolism underlying metabolic disorders such as type 2 diabetes
and obesity (summarized in other reviews [16,164]). The landmark discovery by the Ricci
group showed that mice lacking the mitogen-activated protein kinase p38δ displayed
improved glucose tolerance due to enhanced insulin secretion from pancreatic β cells
and that deletion of p38δ resulted in dramatic activation of PKD and protected against
hyperlipidemia-induced insulin resistance and oxidative stress-imposed pancreatic β cell
apoptosis [24]. Mechanistically, p38δ exerts an inhibitory phosphorylation on PKD1,
which regulated both stimulated insulin secretion and pancreatic β cell survival [24]. This
study identified PKD1 as a crucial regulator of stimulated insulin exocytosis at the TGN,
demonstrating for the first time the biological significance of PKD in protein trafficking
at the TGN. However, several recent studies have revealed an opposite function of PKD1
and -2 in insulin secretion in pancreatic β cells. Bergeron et al. showed that β cell-specific
knockout of PKD1 not only did not downregulate insulin secretion, but rather caused
upregulation of insulin secretion and exacerbated hyperglycemia, hyperinsulinemia, and
glucose intolerance in the PKD1-knockout mice fed with a high-fat diet [165]. Similarly, Xiao
et al. showed that PKD2 deletion also triggered hyperinsulinemia, which preceded insulin
resistance and metabolic disorders in the PKD2-deficient mice [166]. At the molecular level,
PKD2 deletion promoted insulin secretion by β cells through increasing the expression
and activity of L-type Ca2+ channels and subsequently augmenting high glucose- and
membrane depolarization-induced Ca2+ influx, implying that downregulation of PKD2
may contribute to hyperinsulinemia and systemic insulin resistance that underlie metabolic
disorders [166]. PKD3 may play a minor role in regulating insulin secretion from pancreatic
β cells, since it has been shown that PKD1 and PKD2 are the predominant isoforms in the
islets, while PKD3 is more abundant in the exocrine cells [167]. Nonetheless, PKD3 is an
important regulator of glucose and lipid metabolism in other organs. A recent study by the
Sumara group demonstrated that in the liver, PKD3 was the predominant PKD isoform
expressed in hepatocytes and was activated by lipid overload [168]. Functionally, PKD3
suppressed insulin signaling, as indicated by the reduced Akt and mammalian target of
rapamycin complex 1 and 2 (mTORC1 and mTORC2) activities, and promoted insulin
resistance. PKD3-knockout mice also showed improved hepatic insulin-induced glucose
tolerance. Additionally, hepatic deletion of PKD3 increased triglyceride and cholesterol
content in the livers via sterol regulatory element binding protein (SREBP), providing a
negative feedback regulation on hepatic lipid production [168]. There is growing interest
in the role of PKD in metabolism. Current studies have established the crucial role of PKD
in regulation of insulin secretion, insulin signaling, and lipid synthesis. However, the exact
function of each isoform and signaling mechanisms in glucose homeostasis and energy
metabolism remain to be fully defined. Although there are currently no ongoing clinical
trials concerning the PKD family in metabolic disorders, targeting PKD isoforms may still
represent a promising strategy for the treatment of obesity and diabetes.
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3.5. Inflammation-Related Diseases
PKD is a major player in inflammatory processes that are coupled with the develop-
ment of many diseases. PKD is required for the production of proinflammatory cytokines
and chemokines in tumor cells [87], immune cells [169–171], myofibroblasts [172], epithe-
lial cells [173], and endothelial cells [174] in response to various stimuli. PKD regulates
the migration and infiltration of lymphocytes [175] and monocytes [176] and modulates
activities of NF-κB [72], HSP27 [177], and COX-2 [172]—all key regulators of inflammatory
responses. Recently, PKD has also been shown to phosphorylate the Nod-like receptor
protein 3 (NLRP3) inflammasome, a critical mediator of innate immunity and inflammatory
responses, and release it from mitochondria-associated endoplasmic reticulum membranes
adjacent to the Golgi membranes, resulting in inflammasome activation, which is crucial
for maintaining efficient host defense in complex organisms [178].
In line with the important role of PKD in inflammation, PKD has been implicated
in the following inflammatory diseases: pancreatitis [179,180], inflammatory bowel dis-
ease [177], inflammation-induced hyperalgesia [181], hypersensitivity pneumonitis [169],
allergic inflammatory diseases [171], bacterial infection [182], viral infection-induced air-
way inflammation [183], and Sjogren’s syndrome-related inflammation [175]. Specifically,
the Yi group reported that Saccharopolyspora rectivirgula induced activation of PKD1 in
innate immune cells in the lung and that PKD1 was indispensable for Saccharopolyspora
rectivirgula-mediated activation of mitogen-activated protein kinases and NF-κB, as well as
expression of various proinflammatory cytokines and chemokines [169]. Pharmacological
inhibition of PKD attenuated early events of experimental pancreatitis in isolated rat acini
and blocked NF-κB activation and attenuated pancreatic injury in animal models of pan-
creatitis [179]. In addition, a study using human colonic myofibroblasts (an activated or
differentiated form of fibroblasts that responds to inflammatory signals and contributes to
inflammation-associated fibrosis) showed that bradykinin stimulated migration of these
cells via PKD-mediated activation of COX-2 and HSP27, implying a role of PKD in inflam-
matory bowel disease [177]. PKD isoforms are also reported to mediate protease-induced
neurogenic inflammation and pain [184]. Taken together, PKD may be a promising target
for anti-inflammatory therapies.
Fibrosis describes the pathological process of tissue thickening or scarring accompa-
nied by the deposition of collagen and other ECM components [185]. In contrast to acute
inflammatory response, fibrosis is the consequence of chronic inflammation in response
to various pathologic conditions such as viral/bacterial infection, allergic response, tissue
repair, radiation, toxins, and autoimmune reactions [185]. PKD has been implicated in the
progression of heart, liver, and lung fibrosis [146,186–189]. The Olson group reported that
cardiac-specific deletion of PKD1 in mice resulted in diminished fibrosis and improved car-
diac function in response to pressure overload through regulating HDACs and MEF2 [146].
Sin et al. demonstrated that impeding the nuclear translocation of PKD1 was protective
against accumulation of fibrillar collagen and development of the cardiac fibrosis that
accompanied cardiac remodeling following pressure overload [28]. In addition to its role
in the heart, Gan et al. found that PKD was increased and activated in lung epithelial cells
and macrophages in idiopathic pulmonary fibrosis and may participate in the pathogenesis
of this disease [186]. It has also been demonstrated that global Prkd3-knockout and myeloid
cell-specific Prkd3-knockout mice developed spontaneous liver fibrosis [187]. It was found
that PKD3 deletion drives liver fibrosis through activating profibrotic macrophages [187].
Overall, it is evident that PKDs play an indispensable role in fibrotic disorders. Isoforms of
PKD are differentially implicated in fibrosis of different organs, with PKD1 and -2 promot-
ing and PKD3 inhibiting fibrosis. It remains to be determined if these effects are organ- or
isoform-specific. More in-depth investigation on the mechanisms of specific PKD isoforms
in fibrotic processes will help unveil their importance as potential novel therapeutic targets
for this disease.
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3.6. Immune Dysregulation
Since the discovery of PKD as a DAG receptor and a key regulator of NF-κB, a tran-
scriptional factor involved in both innate and adaptive immune response, its involvement
in immune response has been intensely investigated [190,191]. PKDs are expressed in
B and T lymphocytes, macrophages, mast cells, and natural killer cells [17,191]. PKD
has been shown to be involved in the regulation of innate immune response through the
MyD88-dependent Toll-like receptor (TLR) signaling pathway [17,192] and by regulating
NLRP3 inflammasomes at the Golgi [178], class II HDACs in lymphocytes [193,194], and β1
integrin activity in T lymphocytes [195]. PKD2 is also an important signaling component
in natural killer cell activation, which establishes the first line of innate immune defense
against pathogen-infected cells [48]. PKD2 also plays a unique role in controlling T-cell
functions during adaptive immune responses, since PKD2 catalytic activity is required for
effective cytokine production after T-cell receptor activation [143]. PKD is an important
mediator of B-lymphocyte activation [196]. Sokol et al. reported that activation of PKD
was necessary for the synergy between the B-cell Ag receptor and tumor necrosis factor
receptor CD40 in B lymphocytes, and the synergetic interaction provided critical signals
for B-cell differentiation, isotype switching, and B-cell memory [196]. Evidence suggested
that PKD was also involved in T-cell development and function [197,198]. Ishikawa et al.
demonstrated that PKD was required for thymic selection during T-cell development [199].
The authors generated T-cell-specific PKD-deficient (PKD2/PKD3 double-deficient) mice
and found that the generation of CD4+CD8- and CD4-CD8+ single-positive thymocytes
was impaired in these mice [199].
A recent study by the Beutler group reported an excessive T follicular helper cell
(TFH) development, germinal center formation, germinal center B-cell activation, and
anti-DNA antibodies’ production with age in Prkd2-/- mice [200]. The authors demon-
strated that PKD2 bound and phosphorylated Bcl6 (a transcription repressor) to limit
Bcl6 nuclear translocation in CD4+ T cells, resulting in excessive cell autonomous TFH
development [200]. TFH are known to provide signals to B cells to initiate the humoral
immune response to most protein antigens, such as germinal center formation, somatic
hypermutation, and affinity maturation [201]. Thus, increased TFH can increase autoanti-
body or IgE production, leading to autoimmune or allergic diseases [202–204]. Therefore,
more in-depth investigation on the role of PKD in T-cell responses will help to unveil its
importance as a novel therapeutic target.
4. Targeted Inhibition of PKD in Diseases
With growing evidence supporting an important role of PKD in cancer and other
diseases, the development of targeted therapies against aberrant PKD activities has gained
considerable interest. Selective, potent, and structurally distinct pan-PKD small-molecule
inhibitors have been reported, including CID755673 and analogs from our group [205–209],
2,6-naphthyridine and bipyridyl inhibitors and their analogs [210–212], as well as 3,5-
diarylazoles from Novartis [213] and CRT0066101 [214] and CRT5 from Cancer Research
Technology Ltd. [215], which all showed nanomolar inhibitory activities towards PKD.
Among them, CRT0066101 is the most potent and efficacious PKD inhibitor by far, with
demonstrated in vivo antitumor activity in pancreas, colon, breast, and bladder cancer
models [64,109,214,216,217]. Additionally, CRT0066101 and CID755673 also showed effi-
cacy in experimental models of acute pancreatitis [179,180], and CID755673 in diabetes and
diabetic cardiomyopathy models [218,219]. Although currently there are no clinical trials
on PKD inhibitors, these encouraging in vivo results suggest that targeted inhibition of
PKD may be a viable therapeutic strategy for diseases with deregulated PKD signaling.
5. Perspectives and Future Directions
Through persistent efforts of many research groups, our understanding of PKD has
advanced enormously over the past two decades. It has become increasingly clear that
PKD is at the forefront of the DAG signaling network and plays pivotal roles in regulating
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many essential cell functions, such as cell proliferation, movement, secretion, contractility,
and metabolism. Many of these functions stem from the crucial role of PKD in regulating
vesicle trafficking at the TGN, actin dynamics, and gene transcription. In many of the
biological systems examined, PKD appears to function as a key sensor for a variety of
cellular stresses and nutrients, and its activation by these cues triggers compensatory
adaptive responses that serve to maintain or strengthen normal cell functions. However,
chronically, these adaptive responses often result in various pathological conditions and
for PKD, the outcomes, for example, could include stress-induced cardiac hypertrophy [16]
or high-fat-diet-induced hyperinsulinemia and glucose intolerance [165,220].
Among all the diseases discussed in this review, the role of PKD in cancer is by far
the most intensively studied, and yet still the least understood. Aberrant PKD expression
and activity have long been demonstrated in a variety of cancers, and increasing evidence
supports the involvement of PKD in almost all aspects of tumor development, growth,
evasion of apoptosis, angiogenesis, invasion and metastasis, and chemoresistance. Re-
cent new studies have also linked PKD to immune modulation [50], microenvironment
changes [47,91], and metabolic rewiring [221]. These multifaceted roles of PKD in cancer
make it an appealing therapeutic target for cancer treatment. However, the therapeutic
benefit of targeting PKD will likely be complicated by the differential roles of PKD iso-
forms in cancer; in particular, PKD1 has been shown to inhibit tumor cell proliferation in
certain cancers and exert negative regulation on EMT, cell migration, and invasion. It is
unclear if these differences at the cellular level can be extended to in vivo settings, and
the development of tissue-specific PKD mouse models of cancer will be instrumental to
address these questions. Meanwhile, despite the high sequence homology, there are unique
structural features in each PKD isoform, which may account for the isoform-selective
effects of PKD in specific cellular environments. The exact mechanisms underlying their
distinct functionalities remain to be determined.
Besides cancer, PKD has also been studied extensively in the heart and the immune
system, followed by the vasculature, CNS, and muscle. Other emerging areas include
metabolic regulation in the liver, adipose tissue, skeletal muscle, and pancreas. Studies
in these areas clearly demonstrate an important role of PKD in the pathogenesis of sev-
eral major diseases, for example, stress-induced cardiac remodeling, obesity, diabetes,
ischemic stroke, neurodevelopmental disorders, various infectious diseases, fibrosis, and
autoimmune disorders (see Table 2 for a summary on the roles of PKD isoforms in other
human diseases). It is important to note that a repeated theme in the pathogenesis of these
diseases is the activation of PKD by various stresses and the downstream modulation of
multiple common signaling nodes, including NF-κB, VEGF, ERK, Akt/mTOR, class IIa
HDACs, integrin, and PI4KIIIβ. More studies are needed to examine the in vivo functions
of PKD in different disease models and evaluate the therapeutic value of targeting PKD
in these pathological conditions. Moreover, in light of the distinct roles of PKD isoforms
in various pathological processes, it has become increasingly desirable to develop PKD
isoform-selective small molecule inhibitors or even activators. Besides small molecules,
other strategies, such as peptide- or nucleotide-based drugs, could also be exploited for
more selective targeting of PKD. Additionally, identifying effective drug combinations of
PKD inhibitors will not only reduce their toxicity and enhance their therapeutic efficacy,
but also broaden the potential clinical usage of these inhibitors.
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Table 2. Versatile roles of PKD in human diseases besides cancer.
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Table 2. Cont.
Disease PKDs Functions Diseases/Pathologies Targets Ref
Immune
dysregulation
PKD1 - Mast cell activation - Allergic reaction - MCP-1 [191]










activation - HDAC7 [195]
PKD2
- Excessive cell autonomous
T follicular helper cell
development
- Germinal center
development - Bcl6 [200]
- Nature killer cell activation - Innate immuneresponse - IFN-γ, TNF-α [48]
In summary, although significant progress has been made in our understanding of
PKD, much more work is needed in order to clarify the different roles of PKD in various
biological processes and the underlying mechanisms. The use of large-scale genome
sequencing technologies, interrogation of various omics data, and analysis of large cohorts
of patient tissues combined with genome editing technology and the development of new
mouse models will likely shed more insights to the roles of PKD in health and diseases.
The information will also help to design more effective and less toxic therapeutic strategies
and agents to target PKD for the treatment of diseases.
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CNS central nervous system
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References
1. Johannes, F.J.; Prestle, J.; Eis, S.; Oberhagemann, P.; Pfizenmaier, K. PKCu is a novel, atypical member of the protein kinase C
family. J. Biol. Chem. 1994, 269, 6140–6148. [CrossRef]
2. Valverde, A.M.; Sinnett-Smith, J.; Van Lint, J.; Rozengurt, E. Molecular cloning and characterization of protein kinase D: A
target for diacylglycerol and phorbol esters with a distinctive catalytic domain. Proc. Natl. Acad. Sci. USA 1994, 91, 8572–8576.
[CrossRef] [PubMed]
3. Hayashi, A.; Seki, N.; Hattori, A.; Kozuma, S.; Saito, T. PKCnu, a new member of the protein kinase C family, composes a fourth
subfamily with PKCmu. Biochim. Biophys. Acta 1999, 1450, 99–106. [CrossRef]
4. Sturany, S.; Van Lint, J.; Muller, F.; Wilda, M.; Hameister, H.; Hocker, M.; Brey, A.; Gern, U.; Vandenheede, J.; Gress, T.; et al.
Molecular cloning and characterization of the human protein kinase D2. A novel member of the protein kinase D family of serine
threonine kinases. J. Biol. Chem. 2001, 276, 3310–3318. [CrossRef] [PubMed]
5. Reinhardt, R.; Truebestein, L.; Schmidt, H.A.; Leonard, T.A. It Takes Two to Tango: Activation of Protein Kinase D by Dimerization.
Bioessays 2020, 42, e1900222. [CrossRef] [PubMed]
6. Azoitei, N.; Cobbaut, M.; Becher, A.; Van Lint, J.; Seufferlein, T. Protein kinase D2: A versatile player in cancer biology. Oncogene
2018, 37, 1263–1278. [CrossRef]
7. Roy, A.; Ye, J.; Deng, F.; Wang, Q.J. Protein kinase D signaling in cancer: A friend or foe? Biochim. Biophys. Acta Rev. Cancer 2017,
1868, 283–294. [CrossRef]
8. Chen, J.; Giridhar, K.V.; Zhang, L.; Xu, S.; Wang, Q.J. A protein kinase C/protein kinase D pathway protects LNCaP prostate
cancer cells from phorbol ester-induced apoptosis by promoting ERK1/2 and NF-{kappa}B activities. Carcinogenesis 2011, 32,
1198–1206. [CrossRef] [PubMed]
9. LaValle, C.R.; George, K.M.; Sharlow, E.R.; Lazo, J.S.; Wipf, P.; Wang, Q.J. Protein kinase D as a potential new target for cancer
therapy. Biochim. Biophys. Acta 2010, 1806, 183–192. [CrossRef]
10. Waldron, R.T.; Rozengurt, E. Protein kinase C phosphorylates protein kinase D activation loop Ser744 and Ser748 and releases
autoinhibition by the pleckstrin homology domain. J. Biol. Chem. 2003, 278, 154–163.
11. Sundram, V.; Chauhan, S.C.; Jaggi, M. Emerging roles of protein kinase D1 in cancer. Mol. Cancer Res. 2011, 9, 985–996. [CrossRef]
12. Elsner, D.J.; Siess, K.M.; Gossenreiter, T.; Hartl, M.; Leonard, T.A. A ubiquitin-like domain controls protein kinase D dimerization
and activation by trans-autophosphorylation. J. Biol. Chem. 2019, 294, 14422–14441. [CrossRef] [PubMed]
13. Wood, B.M.; Bossuyt, J. Emergency Spatiotemporal Shift: The Response of Protein Kinase D to Stress Signals in the Cardiovascular
System. Front. Pharmacol. 2017, 8, 9. [CrossRef] [PubMed]
14. Durand, N.; Borges, S.; Storz, P. Protein Kinase D Enzymes as Regulators of EMT and Cancer Cell Invasion. J. Clin. Med. 2016,
5, 20. [CrossRef]
15. Rozengurt, E.; Rey, O.; Waldron, R.T. Protein kinase D signaling. J. Biol. Chem. 2005, 280, 13205–13208. [CrossRef]
16. Simsek Papur, O.; Sun, A.; Glatz, J.F.C.; Luiken, J.; Nabben, M. Acute and Chronic Effects of Protein Kinase-D Signaling on
Cardiac Energy Metabolism. Front. Cardiovasc Med. 2018, 5, 65. [CrossRef] [PubMed]
17. Rozengurt, E. Protein kinase D signaling: Multiple biological functions in health and disease. Physiology (Bethesda) 2011, 26, 23–33.
[CrossRef]
18. Prestle, J.; Pfizenmaier, K.; Brenner, J.; Johannes, F.J. Protein kinase C mu is located at the Golgi compartment. J. Cell Biol. 1996,
134, 1401–1410. [CrossRef] [PubMed]
19. Liljedahl, M.; Maeda, Y.; Colanzi, A.; Ayala, I.; Van Lint, J.; Malhotra, V. Protein kinase D regulates the fission of cell surface
destined transport carriers from the trans-Golgi network. Cell 2001, 104, 409–420. [CrossRef]
20. Bossard, C.; Bresson, D.; Polishchuk, R.S.; Malhotra, V. Dimeric PKD regulates membrane fission to form transport carriers at the
TGN. J. Cell Biol. 2007, 179, 1123–1131. [CrossRef]
21. Jamora, C.; Yamanouye, N.; Van Lint, J.; Laudenslager, J.; Vandenheede, J.R.; Faulkner, D.J.; Malhotra, V. Gbetagamma-mediated
regulation of Golgi organization is through the direct activation of protein kinase D. Cell 1999, 98, 59–68. [CrossRef]
22. Baron, C.L.; Malhotra, V. Role of diacylglycerol in PKD recruitment to the TGN and protein transport to the plasma membrane.
Science 2002, 295, 325–328. [CrossRef] [PubMed]
23. Maeda, Y.; Beznoussenko, G.V.; Van Lint, J.; Mironov, A.A.; Malhotra, V. Recruitment of protein kinase D to the trans-Golgi
network via the first cysteine-rich domain. Embo J. 2001, 20, 5982–5990. [CrossRef] [PubMed]
Biomolecules 2021, 11, 483 23 of 30
24. Sumara, G.; Formentini, I.; Collins, S.; Sumara, I.; Windak, R.; Bodenmiller, B.; Ramracheya, R.; Caille, D.; Jiang, H.; Platt, K.A.; et al.
Regulation of PKD by the MAPK p38delta in insulin secretion and glucose homeostasis. Cell 2009, 136, 235–248. [CrossRef]
[PubMed]
25. Hausser, A.; Storz, P.; Martens, S.; Link, G.; Toker, A.; Pfizenmaier, K. Protein kinase D regulates vesicular transport by
phosphorylating and activating phosphatidylinositol-4 kinase IIIbeta at the Golgi complex. Nat. Cell Biol. 2005, 7, 880–886.
[CrossRef] [PubMed]
26. Rey, O.; Yuan, J.; Young, S.H.; Rozengurt, E. Protein kinase C nu/protein kinase D3 nuclear localization, catalytic activation, and
intracellular redistribution in response to G protein-coupled receptor agonists. J. Biol. Chem. 2003, 278, 23773–23785. [CrossRef]
27. Rey, O.; Sinnett-Smith, J.; Zhukova, E.; Rozengurt, E. Regulated nucleocytoplasmic transport of protein kinase D in response to G
protein-coupled receptor activation. J. Biol. Chem. 2001, 276, 49228–49235. [CrossRef]
28. Sin, Y.Y.; Martin, T.P.; Wills, L.; Currie, S.; Baillie, G.S. Small heat shock protein 20 (Hsp20) facilitates nuclear import of protein
kinase D 1 (PKD1) during cardiac hypertrophy. Cell Commun. Signal. 2015, 13, 16. [CrossRef]
29. Auer, A.; von Blume, J.; Sturany, S.; von Wichert, G.; Van Lint, J.; Vandenheede, J.; Adler, G.; Seufferlein, T. Role of the regulatory
domain of protein kinase D2 in phorbol ester binding, catalytic activity, and nucleocytoplasmic shuttling. Mol. Biol Cell 2005, 16,
4375–4385. [CrossRef] [PubMed]
30. von Blume, J.; Knippschild, U.; Dequiedt, F.; Giamas, G.; Beck, A.; Auer, A.; Van Lint, J.; Adler, G.; Seufferlein, T. Phosphorylation
at Ser244 by CK1 determines nuclear localization and substrate targeting of PKD2. Embo J. 2007, 26, 4619–4633. [CrossRef]
[PubMed]
31. Rey, O.; Papazyan, R.; Waldron, R.T.; Young, S.H.; Lippincott-Schwartz, J.; Jacamo, R.; Rozengurt, E. The nuclear import of protein
kinase D3 requires its catalytic activity. J. Biol. Chem. 2006, 281, 5149–5157. [CrossRef] [PubMed]
32. Storz, P.; Doppler, H.; Johannes, F.J.; Toker, A. Tyrosine phosphorylation of protein kinase D in the pleckstrin homology domain
leads to activation. J. Biol. Chem. 2003, 278, 17969–17976. [CrossRef] [PubMed]
33. Doppler, H.; Storz, P. A novel tyrosine phosphorylation site in protein kinase D contributes to oxidative stress-mediated activation.
J. Biol. Chem. 2007, 282, 31873–31881. [CrossRef] [PubMed]
34. Storz, P.; Toker, A. Protein kinase D mediates a stress-induced NF-kappaB activation and survival pathway. EMBO J. 2003, 22,
109–120. [CrossRef]
35. Cowell, C.F.; Doppler, H.; Yan, I.K.; Hausser, A.; Umezawa, Y.; Storz, P. Mitochondrial diacylglycerol initiates protein-kinase
D1-mediated ROS signaling. J. Cell Sci 2009, 122, 919–928. [CrossRef] [PubMed]
36. Storz, P.; Doppler, H.; Toker, A. Protein kinase D mediates mitochondrion-to-nucleus signaling and detoxification from mitochon-
drial reactive oxygen species. Mol. Cell Biol. 2005, 25, 8520–8530. [CrossRef]
37. Cobbaut, M.; Van Lint, J. Function and Regulation of Protein Kinase D in Oxidative Stress: A Tale of Isoforms. Oxid. Med. Cell
Longev. 2018, 2018, 2138502. [CrossRef]
38. Doppler, H.; Storz, P. Mitochondrial and Oxidative Stress-Mediated Activation of Protein Kinase D1 and Its Importance in
Pancreatic Cancer. Front. Oncol. 2017, 7, 41. [CrossRef]
39. Youssef, I.; Ricort, J.M. Deciphering the Role of Protein Kinase D1 (PKD1) in Cellular Proliferation. Mol. Cancer Res. 2019, 17,
1961–1974. [CrossRef]
40. Yuan, J.; Pandol, S.J. PKD signaling and pancreatitis. J. Gastroenterol. 2016, 51, 651–659. [CrossRef]
41. Rashel, M.; Alston, N.; Ghazizadeh, S. Protein kinase D1 has a key role in wound healing and skin carcinogenesis. J. Investig.
Dermatol 2014, 134, 902–909. [CrossRef]
42. Durand, N.; Borges, S.; Storz, P. Functional and therapeutic significance of protein kinase D enzymes in invasive breast cancer.
Cell. Mol. Life Sci 2015, 72, 4369–4382. [CrossRef] [PubMed]
43. Guha, S.; Tanasanvimon, S.; Sinnett-Smith, J.; Rozengurt, E. Role of protein kinase D signaling in pancreatic cancer. Biochem.
Pharmacol. 2010, 80, 1946–1954. [CrossRef]
44. Azoitei, N.; Frohling, S.; Scholl, C.; Seufferlein, T. PRKD2: A two-pronged kinase crucial for the tumor-supporting activity of
HSP90. Mol. Cell Oncol. 2015, 2, e981444. [CrossRef]
45. Azoitei, N.; Diepold, K.; Brunner, C.; Rouhi, A.; Genze, F.; Becher, A.; Kestler, H.; van Lint, J.; Chiosis, G.; Koren, J., 3rd; et al.
HSP90 supports tumor growth and angiogenesis through PRKD2 protein stabilization. Cancer Res. 2014, 74, 7125–7136. [CrossRef]
[PubMed]
46. Ren, B. Protein Kinase D1 Signaling in Angiogenic Gene Expression and VEGF-Mediated Angiogenesis. Front. Cell Dev. Biol.
2016, 4, 37. [CrossRef] [PubMed]
47. Xu, W.; Qian, J.; Zeng, F.; Li, S.; Guo, W.; Chen, L.; Li, G.; Zhang, Z.; Wang, Q.J.; Deng, F. Protein kinase Ds promote tumor
angiogenesis through mast cell recruitment and expression of angiogenic factors in prostate cancer microenvironment. J. Exp.
Clin. Cancer Res. 2019, 38, 114. [CrossRef]
48. Scheiter, M.; Bulitta, B.; van Ham, M.; Klawonn, F.; Konig, S.; Jansch, L. Protein Kinase Inhibitors CK59 and CID755673 Alter
Primary Human NK Cell Effector Functions. Front. Immunol. 2013, 4, 66. [CrossRef]
49. Aicart-Ramos, C.; He, S.D.; Land, M.; Rubin, C.S. A Novel Conserved Domain Mediates Dimerization of Protein Kinase D (PKD)
Isoforms: DIMERIZATION IS ESSENTIAL FOR PKD-DEPENDENT REGULATION OF SECRETION AND INNATE IMMUNITY.
J. Biol. Chem. 2016, 291, 23516–23531. [CrossRef]
Biomolecules 2021, 11, 483 24 of 30
50. Cui, B.; Chen, J.; Luo, M.; Wang, L.; Chen, H.; Kang, Y.; Wang, J.; Zhou, X.; Feng, Y.; Zhang, P. Protein kinase D3 regulates the
expression of the immunosuppressive protein, PDL1, through STAT1/STAT3 signaling. Int. J. Oncol. 2020, 56, 909–920. [CrossRef]
51. Kisfalvi, K.; Hurd, C.; Guha, S.; Rozengurt, E. Induced overexpression of protein kinase D1 stimulates mitogenic signaling in
human pancreatic carcinoma PANC-1 cells. J. Cell Physiol. 2010, 223, 309–316. [CrossRef]
52. Liou, G.Y.; Doppler, H.; Braun, U.B.; Panayiotou, R.; Scotti Buzhardt, M.; Radisky, D.C.; Crawford, H.C.; Fields, A.P.; Murray,
N.R.; Wang, Q.J.; et al. Protein kinase D1 drives pancreatic acinar cell reprogramming and progression to intraepithelial neoplasia.
Nat. Commun. 2015, 6, 6200. [CrossRef]
53. Zhang, L.; Li, Z.; Liu, Y.; Xu, S.; Tandon, M.; Appelboom, B.; LaValle, C.R.; Chiosea, S.I.; Wang, L.; Sen, M.; et al. Analysis of
oncogenic activities of protein kinase D1 in head and neck squamous cell carcinoma. BMC Cancer 2018, 18, 1107. [CrossRef]
54. McEneaney, V.; Dooley, R.; Harvey, B.J.; Thomas, W. Protein kinase D stabilizes aldosterone-induced ERK1/2 MAP kinase
activation in M1 renal cortical collecting duct cells to promote cell proliferation. J. Steroid Biochem. Mol. Biol. 2010, 118, 18–28.
[CrossRef]
55. Tandon, M.; Johnson, J.; Li, Z.; Xu, S.; Wipf, P.; Wang, Q.J. New pyrazolopyrimidine inhibitors of protein kinase d as potent
anticancer agents for prostate cancer cells. PLoS ONE 2013, 8, e75601. [CrossRef]
56. Tandon, M.; Salamoun, J.M.; Carder, E.J.; Farber, E.; Xu, S.; Deng, F.; Tang, H.; Wipf, P.; Wang, Q.J. SD-208, a novel protein kinase
D inhibitor, blocks prostate cancer cell proliferation and tumor growth in vivo by inducing G2/M cell cycle arrest. PLoS ONE
2015, 10, e0119346. [CrossRef]
57. Karam, M.; Legay, C.; Auclair, C.; Ricort, J.M. Protein kinase D1 stimulates proliferation and enhances tumorigenesis of MCF-7
human breast cancer cells through a MEK/ERK-dependent signaling pathway. Exp. Cell Res. 2012, 318, 558–569. [CrossRef]
[PubMed]
58. Karam, M.; Bieche, I.; Legay, C.; Vacher, S.; Auclair, C.; Ricort, J.M. Protein kinase D1 regulates ERalpha-positive breast cancer
cell growth response to 17beta-estradiol and contributes to poor prognosis in patients. J. Cell Mol. Med. 2014, 18, 2536–2552.
[CrossRef] [PubMed]
59. Biswas, M.H.; Du, C.; Zhang, C.; Straubhaar, J.; Languino, L.R.; Balaji, K.C. Protein kinase D1 inhibits cell proliferation through
matrix metalloproteinase-2 and matrix metalloproteinase-9 secretion in prostate cancer. Cancer Res. 2010, 70, 2095–2104. [CrossRef]
[PubMed]
60. Nickkholgh, B.; Sittadjody, S.; Ordonez, K.; Rothberg, M.B.; Balaji, K.C. Protein kinase D1 induces G1-phase cell-cycle arrest
independent of Checkpoint kinases by phosphorylating Cell Division Cycle Phosphatase 25. Prostate 2019, 79, 1053–1058.
[CrossRef]
61. Sundram, V.; Ganju, A.; Hughes, J.E.; Khan, S.; Chauhan, S.C.; Jaggi, M. Protein kinase D1 attenuates tumorigenesis in colon
cancer by modulating beta-catenin/T cell factor activity. Oncotarget 2014, 5, 6867–6884. [CrossRef] [PubMed]
62. Ni, Y.; Wang, L.; Zhang, J.; Pang, Z.; Liu, Q.; Du, J. PKD1 is downregulated in non-small cell lung cancer and mediates the
feedback inhibition of mTORC1-S6K1 axis in response to phorbol ester. Int. J. Biochem. Cell Biol. 2015, 60, 34–42. [CrossRef]
[PubMed]
63. Roy, A.; Veroli, M.V.; Prasad, S.; Wang, Q.J. Protein Kinase D2 Modulates Cell Cycle By Stabilizing Aurora A Kinase at Centrosomes.
Mol. Cancer Res. 2018, 16, 1785–1797. [CrossRef] [PubMed]
64. Wei, N.; Chu, E.; Wipf, P.; Schmitz, J.C. Protein kinase d as a potential chemotherapeutic target for colorectal cancer. Mol. Cancer
Ther 2014, 13, 1130–1141. [CrossRef] [PubMed]
65. Zhou, X.; Xue, P.; Yang, M.; Shi, H.; Lu, D.; Wang, Z.; Shi, Q.; Hu, J.; Xie, S.; Zhan, W.; et al. Protein kinase D2 promotes the
proliferation of glioma cells by regulating Golgi phosphoprotein 3. Cancer Lett 2014, 355, 121–129. [CrossRef] [PubMed]
66. Huck, B.; Duss, S.; Hausser, A.; Olayioye, M.A. Elevated protein kinase D3 (PKD3) expression supports proliferation of triple-
negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation. J. Biol. Chem. 2014, 289, 3138–3147. [CrossRef]
[PubMed]
67. Liu, Y.; Song, H.; Yu, S.; Huang, K.H.; Ma, X.; Zhou, Y.; Yu, S.; Zhang, J.; Chen, L. Protein Kinase D3 promotes the cell proliferation
by activating the ERK1/c-MYC axis in breast cancer. J. Cell Mol. Med. 2020, 24, 2135–2144. [CrossRef]
68. Hao, Q.; McKenzie, R.; Gan, H.; Tang, H. Protein kinases D2 and D3 are novel growth regulators in HCC1806 triple-negative
breast cancer cells. Anticancer Res. 2013, 33, 393–399.
69. Kumari, S.; Khan, S.; Sekhri, R.; Mandil, H.; Behrman, S.; Yallapu, M.M.; Chauhan, S.C.; Jaggi, M. Protein kinase D1 regulates
metabolic switch in pancreatic cancer via modulation of mTORC1. Br. J. Cancer 2020, 122, 121–131. [CrossRef]
70. Trauzold, A.; Schmiedel, S.; Sipos, B.; Wermann, H.; Westphal, S.; Roder, C.; Klapper, W.; Arlt, A.; Lehnert, L.; Ungefroren, H.; et al.
PKCmu prevents CD95-mediated apoptosis and enhances proliferation in pancreatic tumour cells. Oncogene 2003, 22, 8939–8947.
[CrossRef]
71. Wei, N.; Chu, E.; Wu, S.Y.; Wipf, P.; Schmitz, J.C. The cytotoxic effects of regorafenib in combination with protein kinase D
inhibition in human colorectal cancer cells. Oncotarget 2015, 6, 4745–4756. [CrossRef] [PubMed]
72. Mihailovic, T.; Marx, M.; Auer, A.; Van Lint, J.; Schmid, M.; Weber, C.; Seufferlein, T. Protein kinase D2 mediates activation of
nuclear factor kappaB by Bcr-Abl in Bcr-Abl+ human myeloid leukemia cells. Cancer Res. 2004, 64, 8939–8944. [CrossRef]
73. Chen, J.; Deng, F.; Singh, S.V.; Wang, Q.J. Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival
through a PKCepsilon/PKD3 pathway downstream of Akt and ERK 1/2. Cancer Res. 2008, 68, 3844–3853. [CrossRef]
Biomolecules 2021, 11, 483 25 of 30
74. Du, C.; Zhang, C.; Hassan, S.; Biswas, M.H.; Balaji, K.C. Protein kinase D1 suppresses epithelial-to-mesenchymal transition
through phosphorylation of snail. Cancer Res. 2010, 70, 7810–7819. [CrossRef]
75. Zheng, H.; Shen, M.; Zha, Y.L.; Li, W.; Wei, Y.; Blanco, M.A.; Ren, G.; Zhou, T.; Storz, P.; Wang, H.Y.; et al. PKD1 phosphorylation-
dependent degradation of SNAIL by SCF-FBXO11 regulates epithelial-mesenchymal transition and metastasis. Cancer Cell 2014,
26, 358–373. [CrossRef]
76. Jaggi, M.; Rao, P.S.; Smith, D.J.; Wheelock, M.J.; Johnson, K.R.; Hemstreet, G.P.; Balaji, K.C. E-cadherin phosphorylation by protein
kinase D1/protein kinase C{mu} is associated with altered cellular aggregation and motility in prostate cancer. Cancer Res. 2005,
65, 483–492. [PubMed]
77. Du, C.; Jaggi, M.; Zhang, C.; Balaji, K.C. Protein kinase D1-mediated phosphorylation and subcellular localization of beta-catenin.
Cancer Res. 2009, 69, 1117–1124. [CrossRef] [PubMed]
78. Ganju, A.; Chauhan, S.C.; Hafeez, B.B.; Doxtater, K.; Tripathi, M.K.; Zafar, N.; Yallapu, M.M.; Kumar, R.; Jaggi, M. Protein kinase
D1 regulates subcellular localisation and metastatic function of metastasis-associated protein 1. Br. J. Cancer 2018, 118, 587–599.
[CrossRef]
79. Christoforides, C.; Rainero, E.; Brown, K.K.; Norman, J.C.; Toker, A. PKD controls alphavbeta3 integrin recycling and tumor cell
invasive migration through its substrate Rabaptin-5. Dev. Cell 2012, 23, 560–572. [CrossRef]
80. Eiseler, T.; Doppler, H.; Yan, I.K.; Goodison, S.; Storz, P. Protein kinase D1 regulates matrix metalloproteinase expression and
inhibits breast cancer cell invasion. Breast Cancer Res. 2009, 11, R13. [CrossRef]
81. Peterburs, P.; Heering, J.; Link, G.; Pfizenmaier, K.; Olayioye, M.A.; Hausser, A. Protein kinase D regulates cell migration by direct
phosphorylation of the cofilin phosphatase slingshot 1 like. Cancer Res. 2009, 69, 5634–5638. [CrossRef]
82. Merzoug-Larabi, M.; Spasojevic, C.; Eymard, M.; Hugonin, C.; Auclair, C.; Karam, M. Protein kinase C inhibitor Go6976 but not
Go6983 induces the reversion of E- to N-cadherin switch and metastatic phenotype in melanoma: Identification of the role of
protein kinase D1. BMC Cancer 2017, 17, 12. [CrossRef]
83. Zou, Z.; Zeng, F.; Xu, W.; Wang, C.; Ke, Z.; Wang, Q.J.; Deng, F. PKD2 and PKD3 promote prostate cancer cell invasion by
modulating NF-kappaB- and HDAC1-mediated expression and activation of uPA. J. Cell Sci. 2012, 125, 4800–4811. [CrossRef]
84. Wille, C.; Kohler, C.; Armacki, M.; Jamali, A.; Gossele, U.; Pfizenmaier, K.; Seufferlein, T.; Eiseler, T. Protein kinase D2 induces
invasion of pancreatic cancer cells by regulating matrix metalloproteinases. Mol. Biol. Cell 2014, 25, 324–336. [CrossRef]
85. Bernhart, E.; Damm, S.; Wintersperger, A.; DeVaney, T.; Zimmer, A.; Raynham, T.; Ireson, C.; Sattler, W. Protein kinase D2
regulates migration and invasion of U87MG glioblastoma cells in vitro. Exp. Cell Res. 2013, 319, 2037–2048. [CrossRef] [PubMed]
86. Zhu, Y.; Cheng, Y.; Guo, Y.; Chen, J.; Chen, F.; Luo, R.; Li, A. Protein kinase D2 contributes to TNF-alpha-induced epithelial
mesenchymal transition and invasion via the PI3K/GSK-3beta/beta-catenin pathway in hepatocellular carcinoma. Oncotarget
2016, 7, 5327–5341. [CrossRef]
87. LaValle, C.R.; Zhang, L.; Xu, S.; Eiseman, J.L.; Wang, Q.J. Inducible silencing of protein kinase D3 inhibits secretion of tumor-
promoting factors in prostate cancer. Mol. Cancer Ther. 2012, 11, 1389–1399. [CrossRef] [PubMed]
88. Doppler, H.; Bastea, L.I.; Borges, S.; Spratley, S.J.; Pearce, S.E.; Storz, P. Protein kinase d isoforms differentially modulate
cofilin-driven directed cell migration. PLoS ONE 2014, 9, e98090. [CrossRef] [PubMed]
89. Huck, B.; Kemkemer, R.; Franz-Wachtel, M.; Macek, B.; Hausser, A.; Olayioye, M.A. GIT1 phosphorylation on serine 46 by PKD3
regulates paxillin trafficking and cellular protrusive activity. J. Biol. Chem. 2012, 287, 34604–34613. [CrossRef]
90. Ochi, N.; Tanasanvimon, S.; Matsuo, Y.; Tong, Z.; Sung, B.; Aggarwal, B.B.; Sinnett-Smith, J.; Rozengurt, E.; Guha, S. Protein
kinase D1 promotes anchorage-independent growth, invasion, and angiogenesis by human pancreatic cancer cells. J. Cell Physiol.
2011, 226, 1074–1081. [CrossRef] [PubMed]
91. Dong, L.; Yuan, Y.; Opansky, C.; Chen, Y.; Aguilera-Barrantes, I.; Wu, S.; Yuan, R.; Cao, Q.; Cheng, Y.C.; Sahoo, D.; et al.
Diet-induced obesity links to ER positive breast cancer progression via LPA/PKD-1-CD36 signaling-mediated microvascular
remodeling. Oncotarget 2017, 8, 22550–22562. [CrossRef]
92. Azoitei, N.; Pusapati, G.V.; Kleger, A.; Moller, P.; Kufer, R.; Genze, F.; Wagner, M.; van Lint, J.; Carmeliet, P.; Adler, G.; et al.
Protein kinase D2 is a crucial regulator of tumour cell-endothelial cell communication in gastrointestinal tumours. Gut 2010, 59,
1316–1330. [CrossRef] [PubMed]
93. Chen, J.; Feng, Y.; Lu, L.; Wang, H.; Dai, L.; Li, Y.; Zhang, P. Interferon-gamma-induced PD-L1 surface expression on human oral
squamous carcinoma via PKD2 signal pathway. Immunobiology 2012, 217, 385–393. [CrossRef]
94. Zheng, H.; Qian, J.; Baker, D.P.; Fuchs, S.Y. Tyrosine phosphorylation of protein kinase D2 mediates ligand-inducible elimination
of the Type 1 interferon receptor. J. Biol. Chem. 2011, 286, 35733–35741. [CrossRef] [PubMed]
95. Zhukova, E.; Sinnett-Smith, J.; Rozengurt, E. Protein kinase D potentiates DNA synthesis and cell proliferation induced by
bombesin, vasopressin, or phorbol esters in Swiss 3T3 cells. J. Biol. Chem. 2001, 276, 40298–40305. [CrossRef]
96. Rennecke, J.; Rehberger, P.A.; Furstenberger, G.; Johannes, F.J.; Stohr, M.; Marks, F.; Richter, K.H. Protein-kinase-Cmu expression
correlates with enhanced keratinocyte proliferation in normal and neoplastic mouse epidermis and in cell culture. Int. J. Cancer
1999, 80, 98–103. [CrossRef]
97. Yuan, J.; Slice, L.; Walsh, J.H.; Rozengurt, E. Activation of protein kinase D by signaling through the alpha subunit of the
heterotrimeric G protein G(q). J. Biol. Chem. 2000, 275, 2157–2164. [CrossRef] [PubMed]
98. Yuan, J.; Slice, L.W.; Gu, J.; Rozengurt, E. Cooperation of Gq, Gi, and G12/13 in protein kinase D activation and phosphorylation
induced by lysophosphatidic acid. J. Biol. Chem. 2003, 278, 4882–4891. [CrossRef]
Biomolecules 2021, 11, 483 26 of 30
99. Yuan, J.; Slice, L.W.; Rozengurt, E. Activation of protein kinase D by signaling through Rho and the alpha subunit of the
heterotrimeric G protein G13. J. Biol. Chem. 2001, 276, 38619–38627. [CrossRef]
100. Sinnett-Smith, J.; Jacamo, R.; Kui, R.; Wang, Y.M.; Young, S.H.; Rey, O.; Waldron, R.T.; Rozengurt, E. Protein kinase D mediates
mitogenic signaling by Gq-coupled receptors through protein kinase C-independent regulation of activation loop Ser744 and
Ser748 phosphorylation. J. Biol. Chem. 2009, 284, 13434–13445. [CrossRef]
101. Sinnett-Smith, J.; Zhukova, E.; Hsieh, N.; Jiang, X.; Rozengurt, E. Protein kinase D potentiates DNA synthesis induced by
Gq-coupled receptors by increasing the duration of ERK signaling in swiss 3T3 cells. J. Biol. Chem. 2004, 279, 16883–16893.
[CrossRef]
102. Sinnett-Smith, J.; Zhukova, E.; Rey, O.; Rozengurt, E. Protein kinase D2 potentiates MEK/ERK/RSK signaling, c-Fos accumulation
and DNA synthesis induced by bombesin in Swiss 3T3 cells. J. Cell Physiol. 2007, 211, 781–790. [CrossRef]
103. Sinnett-Smith, J.; Ni, Y.; Wang, J.; Ming, M.; Young, S.H.; Rozengurt, E. Protein kinase D1 mediates class IIa histone deacetylase
phosphorylation and nuclear extrusion in intestinal epithelial cells: Role in mitogenic signaling. Am. J. Physiol. Cell Physiol. 2014,
306, C961–C971. [CrossRef]
104. Wang, J.; Han, L.; Sinnett-Smith, J.; Han, L.L.; Stevens, J.V.; Rozengurt, N.; Young, S.H.; Rozengurt, E. Positive cross talk between
protein kinase D and beta-catenin in intestinal epithelial cells: Impact on beta-catenin nuclear localization and phosphorylation at
Ser552. Am. J. Physiol. Cell Physiol. 2016, 310, C542–C557. [CrossRef]
105. Papazyan, R.; Doche, M.; Waldron, R.T.; Rozengurt, E.; Moyer, M.P.; Rey, O. Protein kinase D isozymes activation and localization
during mitosis. Exp. Cell Res. 2008, 314, 3057–3068. [CrossRef] [PubMed]
106. Kienzle, C.; Eisler, S.A.; Villeneuve, J.; Brummer, T.; Olayioye, M.A.; Hausser, A. PKD controls mitotic Golgi complex fragmenta-
tion through a Raf-MEK1 pathway. Mol. Biol Cell 2013, 24, 222–233. [CrossRef]
107. Zhang, T.; Braun, U.; Leitges, M. PKD3 deficiency causes alterations in microtubule dynamics during the cell cycle. Cell Cycle
2016, 15, 1844–1854. [CrossRef] [PubMed]
108. Martinez-Leon, E.; Amable, G.; Jacamo, R.; Picco, M.E.; Anaya, L.; Rozengurt, E.; Rey, O. Protein kinase D1 inhibition interferes
with mitosis progression. J. Cell Physiol. 2019, 234, 20510–20519. [CrossRef]
109. Li, Q.Q.; Hsu, I.; Sanford, T.; Railkar, R.; Balaji, N.; Sourbier, C.; Vocke, C.; Balaji, K.C.; Agarwal, P.K. Protein kinase D inhibitor
CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M. Cell. Mol. Life Sci
2018, 75, 939–963. [CrossRef]
110. Pang, Z.; Wang, Y.; Ding, N.; Chen, X.; Yang, Y.; Wang, G.; Liu, Q.; Du, J. High PKD2 predicts poor prognosis in lung
adenocarcinoma via promoting Epithelial-mesenchymal Transition. Sci Rep. 2019, 9, 1324. [CrossRef] [PubMed]
111. Azoitei, N.; Kleger, A.; Schoo, N.; Thal, D.R.; Brunner, C.; Pusapati, G.V.; Filatova, A.; Genze, F.; Moller, P.; Acker, T.; et al. Protein
kinase D2 is a novel regulator of glioblastoma growth and tumor formation. Neuro-Oncology 2011, 13, 710–724. [CrossRef]
112. Nickkholgh, B.; Sittadjody, S.; Rothberg, M.B.; Fang, X.; Li, K.; Chou, J.W.; Hawkins, G.A.; Balaji, K.C. Beta-catenin represses
protein kinase D1 gene expression by non-canonical pathway through MYC/MAX transcription complex in prostate cancer.
Oncotarget 2017, 8, 78811–78824. [CrossRef] [PubMed]
113. Fang, X.; Gyabaah, K.; Nickkholgh, B.; Cline, J.M.; Balaji, K.C. Novel In Vivo model for combinatorial fluorescence labeling in
mouse prostate. Prostate 2015, 75, 988–1000. [CrossRef]
114. Chen, J.; Lu, L.; Feng, Y.; Wang, H.; Dai, L.; Li, Y.; Zhang, P. PKD2 mediates multi-drug resistance in breast cancer cells through
modulation of P-glycoprotein expression. Cancer Lett. 2011, 300, 48–56. [CrossRef] [PubMed]
115. Chen, J.; Shen, Q.; Labow, M.; Gaither, L.A. Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing
reactivation of MAPK signaling. Cancer Res. 2011, 71, 4280–4291. [CrossRef]
116. Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invesig. 2009, 119, 1420–1428. [CrossRef]
117. Yang, J.; Weinberg, R.A. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev. Cell
2008, 14, 818–829. [CrossRef] [PubMed]
118. van Roy, F.; Berx, G. The cell-cell adhesion molecule E-cadherin. Cell. Mol. Life Sci 2008, 65, 3756–3788. [CrossRef] [PubMed]
119. Bastea, L.I.; Doppler, H.; Balogun, B.; Storz, P. Protein kinase D1 maintains the epithelial phenotype by inducing a DNA-bound,
inactive SNAI1 transcriptional repressor complex. PLoS ONE 2012, 7, e30459. [CrossRef]
120. Bravo-Cordero, J.J.; Magalhaes, M.A.; Eddy, R.J.; Hodgson, L.; Condeelis, J. Functions of cofilin in cell locomotion and invasion.
Nat. Rev. Mol. Cell Biol. 2013, 14, 405–415. [CrossRef]
121. Stossel, T.P.; Fenteany, G.; Hartwig, J.H. Cell surface actin remodeling. J. Cell Sci. 2006, 119, 3261–3264. [CrossRef]
122. Scott, R.W.; Olson, M.F. LIM kinases: Function, regulation and association with human disease. J. Mol. Med. (Berl.) 2007, 85,
555–568. [CrossRef]
123. Niwa, R.; Nagata-Ohashi, K.; Takeichi, M.; Mizuno, K.; Uemura, T. Control of actin reorganization by Slingshot, a family of
phosphatases that dephosphorylate ADF/cofilin. Cell 2002, 108, 233–246. [CrossRef]
124. Eiseler, T.; Doppler, H.; Yan, I.K.; Kitatani, K.; Mizuno, K.; Storz, P. Protein kinase D1 regulates cofilin-mediated F-actin
reorganization and cell motility through slingshot. Nat. Cell Biol. 2009, 11, 545–556. [CrossRef]
125. Spratley, S.J.; Bastea, L.I.; Doppler, H.; Mizuno, K.; Storz, P. Protein kinase D regulates cofilin activity through p21-activated
kinase 4. J. Biol. Chem. 2011, 286, 34254–34261. [CrossRef] [PubMed]
126. Ziegler, S.; Eiseler, T.; Scholz, R.P.; Beck, A.; Link, G.; Hausser, A. A novel protein kinase D phosphorylation site in the tumor
suppressor Rab interactor 1 is critical for coordination of cell migration. Mol. Biol. Cell 2011, 22, 570–580. [CrossRef] [PubMed]
Biomolecules 2021, 11, 483 27 of 30
127. Durand, N.; Bastea, L.I.; Long, J.; Doppler, H.; Ling, K.; Storz, P. Protein Kinase D1 regulates focal adhesion dynamics and cell
adhesion through Phosphatidylinositol-4-phosphate 5-kinase type-l gamma. Sci. Rep. 2016, 6, 35963. [CrossRef] [PubMed]
128. Doppler, H.R.; Bastea, L.I.; Lewis-Tuffin, L.J.; Anastasiadis, P.Z.; Storz, P. Protein kinase D1-mediated phosphorylations regulate
vasodilator-stimulated phosphoprotein (VASP) localization and cell migration. J. Biol. Chem. 2013, 288, 24382–24393. [CrossRef]
[PubMed]
129. Storz, P. Protein kinase D1: Gatekeeper of the epithelial phenotype and key regulator of cancer metastasis? Br. J. Cancer 2018, 118,
459–461. [CrossRef] [PubMed]
130. Onodera, Y.; Nam, J.M.; Hashimoto, A.; Norman, J.C.; Shirato, H.; Hashimoto, S.; Sabe, H. Rab5c promotes AMAP1-PRKD2
complex formation to enhance beta1 integrin recycling in EGF-induced cancer invasion. J. Cell Biol. 2012, 197, 983–996. [CrossRef]
[PubMed]
131. Te Molder, L.; Sonnenberg, A. PKD2 and RSK1 Regulate Integrin beta4 Phosphorylation at Threonine 1736. PLoS ONE 2015, 10,
e0143357. [CrossRef] [PubMed]
132. Borges, S.; Doppler, H.; Perez, E.A.; Andorfer, C.A.; Sun, Z.; Anastasiadis, P.Z.; Thompson, E.; Geiger, X.J.; Storz, P. Pharmacologic
reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis. Breast Cancer Res. 2013,
15, R66. [CrossRef] [PubMed]
133. Alpsoy, A.; Gunduz, U. Protein kinase D2 silencing reduced motility of doxorubicin-resistant MCF7 cells. Tumour Biol. 2015, 36,
4417–4426. [CrossRef]
134. Carmeliet, P. Angiogenesis in health and disease. Nat. Med. 2003, 9, 653–660. [CrossRef] [PubMed]
135. Zhang, X.; Tang, X.; Hamblin, M.H.; Yin, K.J. Long Non-Coding RNA Malat1 Regulates Angiogenesis in Hindlimb Ischemia. Int.
J. Mol. Sci 2018, 19, 1723. [CrossRef]
136. Wulff, C.; Weigand, M.; Kreienberg, R.; Fraser, H.M. Angiogenesis during primate placentation in health and disease. Reproduction
2003, 126, 569–577. [CrossRef]
137. Sun, P.; Zhang, K.; Hassan, S.H.; Zhang, X.; Tang, X.; Pu, H.; Stetler, R.A.; Chen, J.; Yin, K.J. Endothelium-Targeted Deletion of
microRNA-15a/16-1 Promotes Poststroke Angiogenesis and Improves Long-Term Neurological Recovery. Circ. Res. 2020, 126,
1040–1057. [CrossRef]
138. Martiny-Baron, G.; Marme, D. VEGF-mediated tumour angiogenesis: A new target for cancer therapy. Curr. Opin. Biotechnol.
1995, 6, 675–680. [CrossRef]
139. Zhang, X.; Nie, D.; Chakrabarty, S. Growth factors in tumor microenvironment. Front. Biosci. (Landmark Ed.) 2010, 15, 151–165.
[CrossRef]
140. Guo, D.; Jia, Q.; Song, H.Y.; Warren, R.S.; Donner, D.B. Vascular endothelial cell growth factor promotes tyrosine phosphorylation
of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J. Biol. Chem. 1995,
270, 6729–6733. [CrossRef] [PubMed]
141. Wang, Y.; Hoeppner, L.H.; Angom, R.S.; Wang, E.; Dutta, S.; Doeppler, H.R.; Wang, F.; Shen, T.; Scarisbrick, I.A.; Guha, S.; et al.
Protein kinase D up-regulates transcription of VEGF receptor-2 in endothelial cells by suppressing nuclear localization of the
transcription factor AP2beta. J. Biol. Chem. 2019, 294, 15759–15767. [CrossRef]
142. Zhao, D.; Desai, S.; Zeng, H. VEGF stimulates PKD-mediated CREB-dependent orphan nuclear receptor Nurr1 expression: Role
in VEGF-induced angiogenesis. Int. J. Cancer 2011, 128, 2602–2612. [CrossRef] [PubMed]
143. Matthews, S.A.; Navarro, M.N.; Sinclair, L.V.; Emslie, E.; Feijoo-Carnero, C.; Cantrell, D.A. Unique functions for protein kinase D1
and protein kinase D2 in mammalian cells. Biochem. J. 2010, 432, 153–163. [CrossRef]
144. Zhao, D.; Wang, W.; Wang, H.; Peng, H.; Liu, X.; Guo, W.; Su, G.; Zhao, Z. PKD knockdown inhibits pressure overload-induced
cardiac hypertrophy by promoting autophagy via AKT/mTOR pathway. Int. J. Biol. Sci 2017, 13, 276–285. [CrossRef]
145. Vega, R.B.; Harrison, B.C.; Meadows, E.; Roberts, C.R.; Papst, P.J.; Olson, E.N.; McKinsey, T.A. Protein kinases C and D mediate
agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol. Cell Biol. 2004, 24, 8374–8385.
[CrossRef] [PubMed]
146. Fielitz, J.; Kim, M.S.; Shelton, J.M.; Qi, X.; Hill, J.A.; Richardson, J.A.; Bassel-Duby, R.; Olson, E.N. Requirement of protein kinase
D1 for pathological cardiac remodeling. Proc. Natl. Acad. Sci. USA 2008, 105, 3059–3063. [CrossRef] [PubMed]
147. Harrison, B.C.; Kim, M.S.; van Rooij, E.; Plato, C.F.; Papst, P.J.; Vega, R.B.; McAnally, J.A.; Richardson, J.A.; Bassel-Duby, R.; Olson,
E.N.; et al. Regulation of cardiac stress signaling by protein kinase d1. Mol. Cell Biol. 2006, 26, 3875–3888. [CrossRef] [PubMed]
148. Aicart-Ramos, C.; Sanchez-Ruiloba, L.; Gomez-Parrizas, M.; Zaragoza, C.; Iglesias, T.; Rodriguez-Crespo, I. Protein kinase D
activity controls endothelial nitric oxide synthesis. J. Cell Sci. 2014, 127, 3360–3372. [CrossRef]
149. Li, C.; Li, J.; Cai, X.; Sun, H.; Jiao, J.; Bai, T.; Zhou, X.W.; Chen, X.; Gill, D.L.; Tang, X.D. Protein kinase D3 is a pivotal activator of
pathological cardiac hypertrophy by selectively increasing the expression of hypertrophic transcription factors. J. Biol. Chem.
2011, 286, 40782–40791. [CrossRef] [PubMed]
150. Shimizu, I.; Minamino, T. Physiological and pathological cardiac hypertrophy. J. Mol. Cell Cardiol. 2016, 97, 245–262. [CrossRef]
151. Tang, B.L. Protein trafficking mechanisms associated with neurite outgrowth and polarized sorting in neurons. J. Neurochem.
2001, 79, 923–930. [CrossRef]
152. Li, G.; Wang, Y. Protein kinase D: A new player among the signaling proteins that regulate functions in the nervous system.
Neurosci. Bull. 2014, 30, 497–504. [CrossRef]
Biomolecules 2021, 11, 483 28 of 30
153. Yin, D.M.; Huang, Y.H.; Zhu, Y.B.; Wang, Y. Both the establishment and maintenance of neuronal polarity require the activity of
protein kinase D in the Golgi apparatus. J. Neurosci. 2008, 28, 8832–8843. [CrossRef]
154. Higuero, A.M.; Sanchez-Ruiloba, L.; Doglio, L.E.; Portillo, F.; Abad-Rodriguez, J.; Dotti, C.G.; Iglesias, T. Kidins220/ARMS
modulates the activity of microtubule-regulating proteins and controls neuronal polarity and development. J. Biol. Chem. 2010,
285, 1343–1357. [CrossRef] [PubMed]
155. Watkins, J.L.; Lewandowski, K.T.; Meek, S.E.; Storz, P.; Toker, A.; Piwnica-Worms, H. Phosphorylation of the Par-1 polarity kinase
by protein kinase D regulates 14-3-3 binding and membrane association. Proc. Natl. Acad. Sci. USA 2008, 105, 18378–18383.
[CrossRef] [PubMed]
156. Matsumura, K.; Baba, M.; Nagayasu, K.; Yamamoto, K.; Kondo, M.; Kitagawa, K.; Takemoto, T.; Seiriki, K.; Kasai, A.; Ago, Y.; et al.
Autism-associated protein kinase D2 regulates embryonic cortical neuron development. Biochem. Biophys. Res. Commun 2019, 519,
626–632. [CrossRef] [PubMed]
157. Allou, L.; Lambert, L.; Amsallem, D.; Bieth, E.; Edery, P.; Destree, A.; Rivier, F.; Amor, D.; Thompson, E.; Nicholl, J.; et al. 14q12
and severe Rett-like phenotypes: New clinical insights and physical mapping of FOXG1-regulatory elements. Eur. J. Hum. Genet.
2012, 20, 1216–1223. [CrossRef] [PubMed]
158. Vineeth, V.S.; Dutta, U.R.; Tallapaka, K.; Das Bhowmik, A.; Dalal, A. Whole exome sequencing identifies a novel 5Mb deletion
at 14q12 region in a patient with global developmental delay, microcephaly and seizures. Gene 2018, 673, 56–60. [CrossRef]
[PubMed]
159. Ellaway, C.J.; Ho, G.; Bettella, E.; Knapman, A.; Collins, F.; Hackett, A.; McKenzie, F.; Darmanian, A.; Peters, G.B.; Fagan, K.; et al.
14q12 microdeletions excluding FOXG1 give rise to a congenital variant Rett syndrome-like phenotype. Eur. J. Hum. Genet. 2013,
21, 522–527. [CrossRef]
160. Montilla, A.; Mata, G.P.; Matute, C.; Domercq, M. Contribution of P2X4 Receptors to CNS Function and Pathophysiology. Int. J.
Mol. Sci. 2020, 21, 5562. [CrossRef]
161. Pose-Utrilla, J.; Garcia-Guerra, L.; Del Puerto, A.; Martin, A.; Jurado-Arjona, J.; De Leon-Reyes, N.S.; Gamir-Morralla, A.;
Sebastian-Serrano, A.; Garcia-Gallo, M.; Kremer, L.; et al. Excitotoxic inactivation of constitutive oxidative stress detoxification
pathway in neurons can be rescued by PKD1. Nat. Commun. 2017, 8, 2275. [CrossRef]
162. Stetler, R.A.; Gao, Y.; Zhang, L.; Weng, Z.; Zhang, F.; Hu, X.; Wang, S.; Vosler, P.; Cao, G.; Sun, D.; et al. Phosphorylation of HSP27
by protein kinase D is essential for mediating neuroprotection against ischemic neuronal injury. J. Neurosci. 2012, 32, 2667–2682.
[CrossRef] [PubMed]
163. Stetler, R.A.; Cao, G.; Gao, Y.; Zhang, F.; Wang, S.; Weng, Z.; Vosler, P.; Zhang, L.; Signore, A.; Graham, S.H.; et al. Hsp27 protects
against ischemic brain injury via attenuation of a novel stress-response cascade upstream of mitochondrial cell death signaling. J.
Neurosci. 2008, 28, 13038–13055. [CrossRef]
164. Kolczynska, K.; Loza-Valdes, A.; Hawro, I.; Sumara, G. Diacylglycerol-evoked activation of PKC and PKD isoforms in regulation
of glucose and lipid metabolism: A review. Lipids Health Dis. 2020, 19, 113. [CrossRef] [PubMed]
165. Bergeron, V.; Ghislain, J.; Vivot, K.; Tamarina, N.; Philipson, L.H.; Fielitz, J.; Poitout, V. Deletion of Protein Kinase D1 in Pancreatic
beta-Cells Impairs Insulin Secretion in High-Fat Diet-Fed Mice. Diabetes 2018, 67, 71–77. [CrossRef]
166. Xiao, Y.; Wang, C.; Chen, J.Y.; Lu, F.; Wang, J.; Hou, N.; Hu, X.; Zeng, F.; Ma, D.; Sun, X.; et al. Deficiency of PRKD2 triggers
hyperinsulinemia and metabolic disorders. Nat. Commun. 2018, 9, 2015. [CrossRef] [PubMed]
167. Chen, L.A.; Li, J.; Silva, S.R.; Jackson, L.N.; Zhou, Y.; Watanabe, H.; Ives, K.L.; Hellmich, M.R.; Evers, B.M. PKD3 Is the
Predominant Protein Kinase D Isoform in Mouse Exocrine Pancreas and Promotes Hormone-induced Amylase Secretion. J. Biol.
Chem. 2009, 284, 2459–2471. [CrossRef]
168. Mayer, A.E.; Loffler, M.C.; Loza Valdes, A.E.; Schmitz, W.; El-Merahbi, R.; Viera, J.T.; Erk, M.; Zhang, T.; Braun, U.; Heiken-
walder, M.; et al. The kinase PKD3 provides negative feedback on cholesterol and triglyceride synthesis by suppressing insulin
signaling. Sci. Signal. 2019, 12. [CrossRef]
169. Kim, Y.I.; Park, J.E.; Brand, D.D.; Fitzpatrick, E.A.; Yi, A.K. Protein kinase D1 is essential for the proinflammatory response
induced by hypersensitivity pneumonitis-causing thermophilic actinomycetes Saccharopolyspora rectivirgula. J. Immunol. 2010,
184, 3145–3156. [CrossRef]
170. Yamashita, K.; Gon, Y.; Shimokawa, T.; Nunomura, S.; Endo, D.; Miyata, N.; Hashimoto, S.; Van Lint, J.; Ra, C. High affinity
receptor for IgE stimulation activates protein kinase D augmenting activator protein-1 activity for cytokine producing in mast
cells. Int. Immunopharmacol. 2010, 10, 277–283. [CrossRef]
171. Salamon, P.; Shefler, I.; Hershko, A.Y.; Mekori, Y.A. The Involvement of Protein Kinase D in T Cell-Induced Mast Cell Activation.
Int. Arch. Allergy Immunol. 2016, 171, 203–208. [CrossRef]
172. Yoo, J.; Chung, C.; Slice, L.; Sinnett-Smith, J.; Rozengurt, E. Protein kinase D mediates synergistic expression of COX-2 induced by
TNF-{alpha} and bradykinin in human colonic myofibroblasts. Am. J. Physiol Cell Physiol. 2009, 297, C1576–C1587. [CrossRef]
173. Chiu, T.T.; Leung, W.Y.; Moyer, M.P.; Strieter, R.M.; Rozengurt, E. Protein kinase D2 mediates lysophosphatidic acid-induced
interleukin 8 production in nontransformed human colonic epithelial cells through NF-kappaB. Am. J. Physiol. Cell Physiol. 2007,
292, C767–C777. [CrossRef]
174. Hao, Q.; Wang, L.; Tang, H. Vascular endothelial growth factor induces protein kinase D-dependent production of proinflamma-
tory cytokines in endothelial cells. Am. J. Physiol. Cell Physiol. 2009, 296, C821–C827. [CrossRef] [PubMed]
Biomolecules 2021, 11, 483 29 of 30
175. Diebold, Y.; Chen, L.L.; Tepavcevic, V.; Ferdman, D.; Hodges, R.R.; Dartt, D.A. Lymphocytic infiltration and goblet cell marker
alteration in the conjunctiva of the MRL/MpJ-Fas(lpr) mouse model of Sjogren’s syndrome. Exp. Eye Res. 2007, 84, 500–512.
[CrossRef] [PubMed]
176. Tan, M.; Hao, F.; Xu, X.; Chisolm, G.M.; Cui, M.Z. Lysophosphatidylcholine activates a novel PKD2-mediated signaling pathway
that controls monocyte migration. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 1376–1382. [CrossRef] [PubMed]
177. Chu, E.; Saini, S.; Liu, T.; Yoo, J. Bradykinin stimulates protein kinase D-mediated colonic myofibroblast migration via
cyclooxygenase-2 and heat shock protein 27. J. Surg. Res. 2017, 209, 191–198. [CrossRef]
178. Zhang, Z.; Meszaros, G.; He, W.T.; Xu, Y.; de Fatima Magliarelli, H.; Mailly, L.; Mihlan, M.; Liu, Y.; Puig Gamez, M.; Gogi-
nashvili, A.; et al. Protein kinase D at the Golgi controls NLRP3 inflammasome activation. J. Exp. Med. 2017, 214, 2671–2693.
[CrossRef]
179. Yuan, J.; Tan, T.; Geng, M.; Tan, G.; Chheda, C.; Pandol, S.J. Novel Small Molecule Inhibitors of Protein Kinase D Suppress
NF-kappaB Activation and Attenuate the Severity of Rat Cerulein Pancreatitis. Front. Physiol. 2017, 8, 1014. [CrossRef]
180. Yuan, J.; Liu, Y.; Tan, T.; Guha, S.; Gukovsky, I.; Gukovskaya, A.; Pandol, S.J. Protein kinase d regulates cell death pathways in
experimental pancreatitis. Front. Physiol. 2012, 3, 60. [CrossRef]
181. Zhu, H.; Yang, Y.; Zhang, H.; Han, Y.; Li, Y.; Zhang, Y.; Yin, D.; He, Q.; Zhao, Z.; Blumberg, P.M.; et al. Interaction between protein
kinase D1 and transient receptor potential V1 in primary sensory neurons is involved in heat hypersensitivity. Pain 2008, 137,
574–588. [CrossRef] [PubMed]
182. Upadhyay, K.; Park, J.E.; Yoon, T.W.; Halder, P.; Kim, Y.I.; Metcalfe, V.; Talati, A.J.; English, B.K.; Yi, A.K. Group B Streptococci
Induce Proinflammatory Responses via a Protein Kinase D1-Dependent Pathway. J. Immunol. 2017, 198, 4448–4457. [CrossRef]
183. Rezaee, F.; DeSando, S.A.; Ivanov, A.I.; Chapman, T.J.; Knowlden, S.A.; Beck, L.A.; Georas, S.N. Sustained protein kinase D
activation mediates respiratory syncytial virus-induced airway barrier disruption. J. Virol. 2013, 87, 11088–11095. [CrossRef]
184. Amadesi, S.; Grant, A.D.; Cottrell, G.S.; Vaksman, N.; Poole, D.P.; Rozengurt, E.; Bunnett, N.W. Protein kinase D isoforms are
expressed in rat and mouse primary sensory neurons and are activated by agonists of protease-activated receptor 2. J. Comp.
Neurol. 2009, 516, 141–156. [CrossRef]
185. Wynn, T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008, 214, 199–210. [CrossRef]
186. Gan, H.; McKenzie, R.; Hao, Q.; Idell, S.; Tang, H. Protein kinase D is increased and activated in lung epithelial cells and
macrophages in idiopathic pulmonary fibrosis. PLoS ONE 2014, 9, e101983. [CrossRef]
187. Zhang, S.; Liu, H.; Yin, M.; Pei, X.; Hausser, A.; Ishikawa, E.; Yamasaki, S.; Jin, Z.G. Deletion of Protein Kinase D3 Promotes Liver
Fibrosis in Mice. Hepatology 2020, 72, 1717–1734. [CrossRef]
188. Geng, J.; Zhao, Z.; Kang, W.; Wang, W.; Zhang, Y.; Zhiming, G.E. Atorvastatin reverses cardiac remodeling possibly through
regulation of protein kinase D/myocyte enhancer factor 2D activation in spontaneously hypertensive rats. Pharmacol. Res. 2010,
61, 40–47. [CrossRef]
189. Shao, W.; Li, D.; Peng, J.; Chen, S.; Zhou, C.; Cheng, Z.; Yu, Y.; Li, H.; Li, C.; You, Y.; et al. Inhibitory effect of ethyl acetate extract
of Aristolochia yunnanensis on cardiac fibrosis through extracellular signal-regulated kinases 1/2 and transforming growth
factor beta/small mother against decapentaplegic signaling pathways. Transl. Res. 2014, 163, 160–170. [CrossRef] [PubMed]
190. Davidson-Moncada, J.K.; Lopez-Lluch, G.; Segal, A.W.; Dekker, L.V. Involvement of protein kinase D in Fc gamma-receptor
activation of the NADPH oxidase in neutrophils. Biochem. J. 2002, 363, 95–103. [CrossRef] [PubMed]
191. Murphy, T.R.; Legere, H.J., 3rd; Katz, H.R. Activation of protein kinase D1 in mast cells in response to innate, adaptive, and
growth factor signals. J. Immunol. 2007, 179, 7876–7882. [CrossRef] [PubMed]
192. Park, J.E.; Kim, Y.I.; Yi, A.K. Protein kinase D1 is essential for MyD88-dependent TLR signaling pathway. J. Immunol. 2009, 182,
6316–6327. [CrossRef] [PubMed]
193. Parra, M.; Kasler, H.; McKinsey, T.A.; Olson, E.N.; Verdin, E. Protein kinase D1 phosphorylates HDAC7 and induces its nuclear
export after T-cell receptor activation. J. Biol. Chem. 2005, 280, 13762–13770. [CrossRef] [PubMed]
194. Matthews, S.A.; Liu, P.; Spitaler, M.; Olson, E.N.; McKinsey, T.A.; Cantrell, D.A.; Scharenberg, A.M. Essential role for protein
kinase D family kinases in the regulation of class II histone deacetylases in B lymphocytes. Mol. Cell Biol. 2006, 26, 1569–1577.
[CrossRef]
195. Medeiros, R.B.; Dickey, D.M.; Chung, H.; Quale, A.C.; Nagarajan, L.R.; Billadeau, D.D.; Shimizu, Y. Protein kinase D1 and the
beta 1 integrin cytoplasmic domain control beta 1 integrin function via regulation of Rap1 activation. Immunity 2005, 23, 213–226.
[CrossRef] [PubMed]
196. Haxhinasto, S.A.; Bishop, G.A. A novel interaction between protein kinase D and TNF receptor-associated factor molecules
regulates B cell receptor-CD40 synergy. J. Immunol. 2003, 171, 4655–4662. [CrossRef] [PubMed]
197. Irie, A.; Chen, Y.Z.; Tsukamoto, H.; Jotsuka, T.; Masuda, M.; Nishimura, Y. Unique T cell proliferation associated with PKCmu
activation and impaired ZAP-70 phosphorylation in recognition of overexpressed HLA/partially agonistic peptide complexes.
Eur. J. Immunol. 2003, 33, 1497–1507. [CrossRef]
198. Spitaler, M.; Emslie, E.; Wood, C.D.; Cantrell, D. Diacylglycerol and protein kinase D localization during T lymphocyte activation.
Immunity 2006, 24, 535–546. [CrossRef]
199. Ishikawa, E.; Kosako, H.; Yasuda, T.; Ohmuraya, M.; Araki, K.; Kurosaki, T.; Saito, T.; Yamasaki, S. Protein kinase D regulates
positive selection of CD4(+) thymocytes through phosphorylation of SHP-1. Nat. Commun. 2016, 7, 12756. [CrossRef] [PubMed]
Biomolecules 2021, 11, 483 30 of 30
200. Misawa, T.; SoRelle, J.A.; Choi, J.H.; Yue, T.; Wang, K.W.; McAlpine, W.; Wang, J.; Liu, A.; Tabeta, K.; Turer, E.E.; et al. Mutual
inhibition between Prkd2 and Bcl6 controls T follicular helper cell differentiation. Sci. Immunol. 2020, 5. [CrossRef] [PubMed]
201. Crotty, S. T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. Immunity 2019, 50, 1132–1148. [CrossRef]
[PubMed]
202. Simpson, N.; Gatenby, P.A.; Wilson, A.; Malik, S.; Fulcher, D.A.; Tangye, S.G.; Manku, H.; Vyse, T.J.; Roncador, G.; Hutt-
ley, G.A.; et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of
severe systemic lupus erythematosus. Arthritis Rheum 2010, 62, 234–244. [CrossRef] [PubMed]
203. Vinuesa, C.G.; Cook, M.C.; Angelucci, C.; Athanasopoulos, V.; Rui, L.; Hill, K.M.; Yu, D.; Domaschenz, H.; Whittle, B.;
Lambe, T.; et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity.
Nature 2005, 435, 452–458. [CrossRef] [PubMed]
204. Harada, Y.; Tanaka, S.; Motomura, Y.; Harada, Y.; Ohno, S.; Ohno, S.; Yanagi, Y.; Inoue, H.; Kubo, M. The 3’ enhancer CNS2 is a
critical regulator of interleukin-4-mediated humoral immunity in follicular helper T cells. Immunity 2012, 36, 188–200. [CrossRef]
205. Sharlow, E.R.; Giridhar, K.V.; LaValle, C.R.; Chen, J.; Leimgruber, S.; Barrett, R.; Bravo-Altamirano, K.; Wipf, P.; Lazo, J.S.; Wang,
Q.J. Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone. J. Biol. Chem. 2008, 283,
33516–33526. [CrossRef]
206. Bravo-Altamirano, K.; George, K.M.; Frantz, M.C.; Lavalle, C.R.; Tandon, M.; Leimgruber, S.; Sharlow, E.R.; Lazo, J.S.; Wang, Q.J.;
Wipf, P. Synthesis and Structure-Activity Relationships of Benzothienothiazepinone Inhibitors of Protein Kinase D. ACS Med.
Chem. Lett. 2011, 2, 154–159. [CrossRef] [PubMed]
207. George, K.M.; Frantz, M.C.; Bravo-Altamirano, K.; Lavalle, C.R.; Tandon, M.; Leimgruber, S.; Sharlow, E.R.; Lazo, J.S.; Wang, Q.J.;
Wipf, P. Design, Synthesis, and Biological Evaluation of PKD Inhibitors. Pharmaceutics 2011, 3, 186–228. [CrossRef]
208. Lavalle, C.R.; Bravo-Altamirano, K.; Giridhar, K.V.; Chen, J.; Sharlow, E.; Lazo, J.S.; Wipf, P.; Wang, Q.J. Novel protein kinase D
inhibitors cause potent arrest in prostate cancer cell growth and motility. BMC Chem. Biol. 2010, 10, 5. [CrossRef]
209. Sharlow, E.R.; Mustata Wilson, G.; Close, D.; Leimgruber, S.; Tandon, M.; Reed, R.B.; Shun, T.Y.; Wang, Q.J.; Wipf, P.; Lazo, J.S.
Discovery of diverse small molecule chemotypes with cell-based PKD1 inhibitory activity. PLoS ONE 2011, 6, e25134. [CrossRef]
210. Monovich, L.; Vega, R.B.; Meredith, E.; Miranda, K.; Rao, C.; Capparelli, M.; Lemon, D.D.; Phan, D.; Koch, K.A.; Chapo, J.A.; et al.
A novel kinase inhibitor establishes a predominant role for protein kinase D as a cardiac class IIa histone deacetylase kinase.
FEBS Lett. 2010, 584, 631–637. [CrossRef]
211. Meredith, E.L.; Beattie, K.; Burgis, R.; Capparelli, M.; Chapo, J.; Dipietro, L.; Gamber, G.; Enyedy, I.; Hood, D.B.; Hosagra-
hara, V.; et al. Identification of potent and selective amidobipyridyl inhibitors of protein kinase D. J. Med. Chem. 2010, 53,
5422–5438. [CrossRef]
212. Meredith, E.L.; Ardayfio, O.; Beattie, K.; Dobler, M.R.; Enyedy, I.; Gaul, C.; Hosagrahara, V.; Jewell, C.; Koch, K.; Lee, W.; et al.
Identification of orally available naphthyridine protein kinase D inhibitors. J. Med. Chem. 2010, 53, 5400–5421. [CrossRef]
[PubMed]
213. Gamber, G.G.; Meredith, E.; Zhu, Q.; Yan, W.; Rao, C.; Capparelli, M.; Burgis, R.; Enyedy, I.; Zhang, J.H.; Soldermann, N.; et al.
3,5-diarylazoles as novel and selective inhibitors of protein kinase D. Bioorg. Med. Chem. Lett. 2011, 21, 1447–1451. [CrossRef]
[PubMed]
214. Harikumar, K.B.; Kunnumakkara, A.B.; Ochi, N.; Tong, Z.; Deorukhkar, A.; Sung, B.; Kelland, L.; Jamieson, S.; Sutherland, R.;
Raynham, T.; et al. A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo.
Mol. Cancer Ther. 2010, 9, 1136–1146. [CrossRef] [PubMed]
215. Evans, I.M.; Bagherzadeh, A.; Charles, M.; Raynham, T.; Ireson, C.; Boakes, A.; Kelland, L.; Zachary, I.C. Characterization of the
biological effects of a novel protein kinase D inhibitor in endothelial cells. Biochem. J. 2010, 429, 565–572. [CrossRef]
216. Borges, S.; Perez, E.A.; Thompson, E.A.; Radisky, D.C.; Geiger, X.J.; Storz, P. Effective Targeting of Estrogen Receptor-Negative
Breast Cancers with the Protein Kinase D Inhibitor CRT0066101. Mol. Cancer Ther. 2015, 14, 1306–1316. [CrossRef]
217. Liu, Y.; Wang, Y.; Yu, S.; Zhou, Y.; Ma, X.; Su, Q.; An, L.; Wang, F.; Shi, A.; Zhang, J.; et al. The Role and Mechanism of CRT0066101
as an Effective Drug for Treatment of Triple-Negative Breast Cancer. Cell Physiol. Biochem. 2019, 52, 382–396. [CrossRef]
218. Pasquier, A.; Vivot, K.; Erbs, E.; Spiegelhalter, C.; Zhang, Z.; Aubert, V.; Liu, Z.; Senkara, M.; Maillard, E.; Pinget, M.; et al.
Lysosomal degradation of newly formed insulin granules contributes to beta cell failure in diabetes. Nat. Commun. 2019, 10, 3312.
[CrossRef]
219. Venardos, K.; De Jong, K.A.; Elkamie, M.; Connor, T.; McGee, S.L. The PKD inhibitor CID755673 enhances cardiac function in
diabetic db/db mice. PLoS ONE 2015, 10, e0120934. [CrossRef] [PubMed]
220. Renton, M.C.; McGee, S.L.; Howlett, K.F. The role of protein kinase D (PKD) in intracellular nutrient sensing and regulation of
adaptive responses to the obese environment. Obes. Rev. 2020. [CrossRef]
221. Chen, J.; Cui, B.; Fan, Y.; Li, X.; Li, Q.; Du, Y.; Feng, Y.; Zhang, P. Protein kinase D1 regulates hypoxic metabolism through
HIF-1alpha and glycolytic enzymes incancer cells. Oncol. Rep. 2018, 40, 1073–1082. [CrossRef] [PubMed]
